

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

COVID-19 Post-acute Care Major Organ Damage: A Systematic Review

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2022-061245
Article Type:	Original research
Date Submitted by the Author:	20-Jan-2022
Complete List of Authors:	Greer, Nancy; Minneapolis VA Health Care System Bart, Bradley; University of Minnesota, Department of Medicine; Minneapolis VA Health Care System Billington, Charles ; University of Minnesota; Minneapolis VA Health Care System Diem, Susan; University of Minnesota; Minneapolis VA Health Care System Ensrud, Kristine; University on Minnesota, Department of Medicine; Minneapolis VA Health Care System Kaka, Anjum; University of Minnesota, Department of Medicine; Minneapolis VA Health Care System Klein, Mark; University of Minnesota, Department of Medicine; Minneapolis VA Health Care System Melzer, Anne; Minneapolis Veterans Affairs Health Care System, Pulmonary, Allergy, Critical Care, and Sleep Medicine; University of Minnesota, Department of Medicine Reule, Scott; University of Minnesota, Department of Medicine; Minneapolis VA Health Care System Shaukat, Aasma; Univeristy of Minnesota, Department of Medicine, Division of Gastroenterology; Veterans Affairs Medical Center, Sheets, Kerry; Minneapolis VA Health Care System; Hennepin Healthcare Starks, Jamie; University of Minnesota, Department of Medicine; Minneapolis VA Health Care System Vardeny, Orly; University of Minnesota; Minneapolis VA Health Care System McKenzie, Lauren; Minneapolis VA Health Care System Stroebe, Benjamin; Minneapolis VA Health Care System Macdonald, Roderick; Minneapolis VA Health Care System Sowerby, Katie; Minneapolis VA Health Care System Duan-Porter, Wei; Minneapolis VA Health Care System; University of Minnesota, Department of Medicine Wilt, Timothy; Minneapolis VA Health Care System, Center for Care Delivery and Outcomes Research; University of Minnesota Twin Cities, Department of Medicine
Keywords:	COVID-19, STATISTICS & RESEARCH METHODS, INFECTIOUS DISEASES



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

BMJ Open: first published as 10.1136/bmjopen-2022-061245 on 24 August 2022. Downloaded from <http://bmjopen.bmj.com/> on April 18, 2024 by guest. Protected by copyright.



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

COVID-19 Post-acute Care Major Organ Damage: A Systematic Review

Nancy Greer, PhD¹; Bradley Bart, MD^{2,3}; Charles J. Billington, MD^{2,4}; Susan J. Diem, MD, MPH^{1,2,5,6}; Kristine E. Ensrud, MD, MPH^{1,2,5,6}; Anjum Kaka, MD^{2,7}; Mark Klein, MD^{2,8}; Anne C. Melzer, MD, MS^{2,9}; Scott Reule, MD^{2,10}; Aasma Shaukat, MD, MPH^{1,2,11}; Kerry Sheets, MD^{1,2,12}; Jamie Starks, MD^{2,13}; Orly Vardeny, PharmD, MS^{1,2,14}; Lauren McKenzie, MPH¹; Benjamin Stroebel, MPH¹; Roderick MacDonald, MS¹; Katie Sowerby, BA¹; Wei Duan-Porter, MD, PhD^{1,2,5}; Timothy J. Wilt, MD, MPH^{1,2,5,15}

1. Center for Care Delivery and Outcomes Research, Minneapolis VA Health Care System, Minneapolis, MN
2. Department of Medicine, University of Minnesota, Minneapolis, MN
3. Division of Cardiology, Minneapolis VA Health Care System, Minneapolis, MN
4. Section of Endocrinology and Metabolism, Department of Medicine, Minneapolis VA Health Care System, Minneapolis, MN
5. General Internal Medicine, Minneapolis VA Health Care System, Minneapolis, MN
6. Division of Epidemiology and Community Health, University of Minnesota School of Public Health, Minneapolis, MN
7. Section of Infectious Diseases, Minneapolis VA Health Care System, Minneapolis, MN
8. Hematology/Oncology Section, Minneapolis VA Health Care System, Minneapolis, MN
9. Division of Pulmonary, Allergy, Critical Care, and Sleep Medicine, Minneapolis VA Health Care System, Minneapolis, MN
10. Division of Nephrology, Minneapolis VA Health Care System, Minneapolis, MN
11. Division of Gastroenterology, Minneapolis VA Health Care System, Minneapolis, MN
12. Division of Geriatrics, Hennepin Healthcare, Minneapolis, MN
13. Geriatric Research, Education, and Clinical Center, Minneapolis VA Health Care System, Minneapolis, MN
14. Department of Pharmacy, Minneapolis VA Health Care System, Minneapolis, MN
15. Division of Health Policy and Management, University of Minnesota School of Public Health, Minneapolis, MN

Corresponding Author

Nancy Greer, PhD

Minneapolis VA Health Care System

1 Veterans Drive

Minneapolis, MN 55417

Nancy.Greer@va.gov

612-467-4232

Abstract Word Count: 285

Manuscript Word Count: 3882

References: 30

Tables: 1

Figures: 1

Supplemental Tables: 4

ABSTRACT

Objective: To examine major organ damage after discharge among adults hospitalized for coronavirus disease-2019 (COVID-19) compared with non-COVID-19 controls.

Design: Systematic review

Data sources and study selection: Multiple databases from January 1, 2020 to May 19, 2021. We included English language studies of adults discharged from hospital for COVID-19 and reporting major organ damage.

Data analysis and study quality: Outcome data could not be pooled due to heterogeneity in populations, study designs, and methods of outcome assessment; findings are narratively synthesized. Study quality characteristics were assessed using the Joanna Briggs Institute Appraisal Checklist for Cohort Studies.

Results: Of 124 studies included in a full evidence report, 9 included non-COVID controls and are described here. Four of the 9 (3 US, one UK) used large administrative databases. Four of the remaining 5 studies enrolled fewer than 600 COVID-19 patients. Mean or median age ranged from 49-70 years with 46-94% male and 48-78% White race; 10-40% had been in intensive care units. Follow-up ranged from 4-22 weeks post-discharge. Control groups varied. Four used hospitalized controls, three non-hospitalized controls, and two were unclear. Studies used various definitions of, and methods to assess, major organ damage outcomes. While the magnitude of effect differed across studies, incident cardiac, pulmonary, liver, acute and chronic kidney, stroke, diabetes, and coagulation disorders were consistently greater in adults hospitalized for COVID-19 compared with non-COVID-19 controls.

Conclusions: Post-acute COVID-19 major organ damage is common and likely higher than controls.

There is substantial uncertainty due to evidence limitations. Applicability to subgroups (age, gender, COVID severity, vaccination status) and non-hospitalized patients is unknown. More consistent reporting of clinical outcomes and pre-COVID health status as well as careful selection of control groups is needed to address evidence gaps.

PROSPERO registration number CRD42020204788.

STRENGTHS AND LIMITATIONS OF THIS STUDY

- This systematic review examines clinically relevant major organ damage following hospitalization for COVID-19 as reported in studies with a non-COVID-19 comparator group.
- We defined “post-acute COVID” as post-hospital discharge; applicability of findings to non-hospitalized patients with acute COVID symptoms is unclear.
- Meta-analysis was inappropriate due to heterogeneity in populations, study designs, and methods of outcome assessment.

INTRODUCTION

Coronavirus disease-2019 (COVID-19) is a viral illness that, as of January 15, 2022, was identified in over 328 million individuals (over 66 million in the US)

(<https://www.who.int/emergencies/diseases/novel-coronavirus-2019>, <https://coronavirus.jhu.edu/>). Over 5.5 million deaths worldwide, over 852,000 in the US, are attributed to COVID-19.

In addition to the potential for severe acute pulmonary disease associated with coronavirus infections, there have been numerous reports of other major organ system manifestations and complications in patients hospitalized for COVID-19.¹⁻¹² These studies typically lacked controls without COVID-19 and it is not clear if post-discharge major organ system damage differs in patients hospitalized for COVID-19 from similar individuals without COVID-19.

Multi-organ damage¹³ and long-term clinical outcomes¹⁴ following infection with other coronaviruses such as severe acute respiratory syndrome (SARS) and Middle East Respiratory syndrome (MERS), have been previously reported. Because many COVID-19 patients are admitted to intensive care units, outcomes similar to those observed in post-intensive care syndrome or post-sepsis syndrome may be long-term consequences of COVID-19.¹⁵

We assessed post-acute care major organ damage prevalence in adults hospitalized for COVID-19 and determined if these differ compared with adults without COVID-19. Our review is limited to post-hospital major organ damage; a subset of post-acute sequelae of SARS-CoV-2 infection (PASC)

(<https://www.nih.gov/about-nih/who-we-are/nih-director/statements/nih-launches-new-initiative-study>).

This manuscript is based on a living review conducted for the Department of Veterans Affairs (VA) Evidence Synthesis Program (ESP). The full review is available at: (Link will be added)

METHODS

This review was conducted in accordance with PRISMA standards. For the initial ESP living review (December 2020) and first update (June 2021), we included studies of adults hospitalized for *or with*

laboratory confirmed COVID-19. We prioritized post-acute major organ damage of greatest clinical relevance. We defined post-acute to include major organ damage reported at discharge or any time post-discharge. We included studies reporting relevant symptoms (such as dyspnea), laboratory data, or radiologic studies consistent with presence of a disease. We excluded studies reporting only general symptoms or studies reporting only mean/median values. For the September 2021 (final) update, we reported outcomes post-discharge and limited to studies with ≥ 50 COVID-19 patients.

We focus this manuscript on major organ damage from studies with at least 50 COVID-19 cases and any non-COVID-19 controls. In all studies, cases were hospitalized for COVID-19 (ie, none were hospitalized for another condition with a subsequent positive test for SARS-CoV-2).

Data Sources and Searches

We searched MEDLINE, Embase, and the Cochrane Library from January 1, 2019 through May 19, 2021. The search strategy (Supplemental Table 1) was developed with input from expert medical librarians. We reviewed non-peer-reviewed public postings about post-COVID-19 complications for links to peer-reviewed data reports.

Study Selection

Consistent with rapid review methods, abstracts were reviewed by one investigator. A subset of 200 abstracts underwent dual independent review with substantial agreement between the two investigators. All articles identified as potentially eligible based on abstract review were independently reviewed by two investigators at the full-text level. Reasons for exclusion were noted. Conflicts were resolved by discussion. Inclusion and exclusion criteria are reported in Table 1.

Table 1. Study Eligibility Criteria

Study Characteristic	Include	Exclude
Population	Adults (age 18 and older); at least 50 case patients for manuscript	Children or adolescents, age <18; MERS; SARS
Intervention	Discharge from hospitalization after admission with or for proven COVID-19 ^a	Data only collected from patients during ongoing hospital acute-care admission with or for proven COVID-19
Comparator	Discharge from hospitalization for individuals without COVID-19 (ideally another respiratory condition); a comparator was not required for the living review but only studies with a control group are included in the manuscript	Not applicable
Outcomes	Prevalence and severity of major organ damage (respiratory, renal, cardiovascular, hematologic, neurologic and cognitive, endocrine, gastrointestinal, and hematologic); healthcare or service use needs related to major organ damage ^b	No outcomes of interest
Timing	Short-term (< 3 months) and long-term (≥ 3 months) post-discharge	Not applicable
Setting	Any post-discharge setting (eg, home, rehabilitation or long-term care facility); may include re-hospitalization	Not applicable
Study Designs	Cohort, case series, other observational; may prioritize articles using a best-evidence approach	Case report, narrative review, descriptive/opinion article with no data

^aIn the original and first update of the living review, we reported outcomes at the time of discharge. For the September 2021 update and this manuscript, patients must be discharged with post-discharge outcome data available.

^bIn the original version of the living review, we included studies reporting “re-positive” RT-PCR test results following discharge. For the June 2021 update and later versions, we excluded studies only reporting “re-positive” test results and removed those studies from the original set of included studies. As more information about the natural history of SARS-CoV-2 has become available, it has been recognized that patients may be PCR positive for prolonged periods after an initial COVID illness, and an isolated PCR positivity in such patients (especially for the first 90 days after diagnosis) does not by itself reflect a new infection. Healthcare or service use needs outcomes are not reported in the manuscript.

Data Extraction and Quality Assessment

Study characteristics (location, design, funding), inclusion and exclusion criteria, baseline demographic data (age, sex, race, comorbidities), hospitalization characteristics (COVID-19 severity, ICU admission, mechanical ventilation, length of hospital stay), length of time post-hospital, and outcomes were extracted by one investigator and verified by a second. Discrepancies were resolved by discussion.

We assessed study quality using the Joanna Briggs Institute Appraisal Checklist for Cohort Studies¹⁶ taking into account similarity between groups, assessment of the exposure and outcomes, adjustment for confounding factors, and completeness of follow-up.

Data Synthesis and Analysis

Due to heterogeneity in populations, study designs, and methods of outcome assessment, we were unable to pool outcomes data. We narratively synthesized the evidence.

Patient and Public Involvement: Neither patients nor the public were involved in this research.

Role of the Funding Source

This review is based on a living rapid review conducted for the VA Evidence Synthesis Program. and funded by the Veterans Health Administration Office of Research and Development, Health Services Research and Development Service. The funding source assigned the topic but was not involved in the study design, data collection, analysis, manuscript preparation, or submission.

RESULTS

Overview of Studies

Our literature search and study selection process are depicted in the Figure. From the 124 eligible references, 9 included controls.¹⁷⁻²⁵ Study inclusion and exclusion criteria, patient demographics, COVID-19, and hospitalization characteristics are reported in Supplemental Table 2.

In 7 of the 9 studies, controls were required to have either no positive COVID-19 test, diagnosis, or hospital admission for COVID-19,^{19-21,23} been quarantined at home for at least 3 months prior to study enrollment,²⁵ or been a patient in 2019 prior to COVID-19.^{17,24} Four studies included hospitalized controls,^{17,19,21,24} 3 included non-hospitalized controls,^{18,23,25} and 2 were unclear.^{20,22} Six studies created matched COVID-19 and control groups, matching on age, sex, race/ethnicity, geographic location, prior patient encounters, and comorbidities (Supplemental Table 2).^{17-20,22,23} One study adjusted for demographic and comorbidity factors²¹ and one recruited volunteers with “similar demographic characteristics”.²⁵

1
2
3 A total of 109,591 COVID-19 patients and 127,089 controls were enrolled. Four studies used
4 administrative data bases (3 from the US and 1 from the UK) with sample sizes ranging from 13,654 to
5 47,780 COVID-19 patients.¹⁷⁻²⁰ The other 5 studies (2 from the UK, and 1 each from the US, Germany,
6 and China) enrolled from 58 to 1,877 COVID-19 patients.²¹⁻²⁵ Five studies reported outcomes
7 (Supplemental Table 3) for multiple organ systems^{17-20,23} while 4 focused on a single system –
8 cardiovascular,^{22,25} renal,²¹ or hematological.²⁴
9
10
11
12
13
14
15

16 In 5 studies reporting age, mean or median age ranged from 49-70 years.^{17,22,23,25} The percentage of males,
17 reported in 6 studies, ranged from 46-94%.^{17-19,22-25} There were no statistically significant differences
18 between COVID-19 and control groups for age or sex in any study.
19
20
21
22
23

24 Race was reported in 5 studies. In a study of US Veterans, 58% of the COVID-19 group and 73% of the
25 seasonal influenza control group were White.¹⁷ In a UK study, 78% of the COVID-19 group and 97% of
26 community-based controls were White.²³ In a US study, 41% of the COVID-19 group and 75% of the
27 non-COVID-19 group were White.²¹ In two other studies reporting race, the COVID-19 and control
28 groups were similar.^{18,19}
29
30
31
32
33
34

35 None of the large database studies reported on COVID-19 severity. Among the other 5 studies, one
36 identified the hospitalized subgroup as having severe COVID-19.²² One study included only patients with
37 moderate to severe COVID-19²³ while in another, 39% were identified as severe or critical.²⁵ The
38 percentage of COVID-19 patients receiving invasive mechanical ventilation or extracorporeal membrane
39 oxygenation ranged from 6-29% (k=3).
40
41
42
43
44
45
46

47 Study quality assessments are reported in Supplemental Table 4. Only 2 studies recruited COVID-19 and
48 control patients from the same populations (ie, concurrent, hospitalized patients).^{19,21} All but 2^{24,25} dealt
49 with potential confounders using matching or adjusted analyses. In most studies, the outcome of interest
50 was a new, post-COVID-19 event. In the database studies, events were identified with International
51 Classification of Diseases version 10 (ICD-10) codes while the smaller studies used laboratory testing,
52
53
54
55
56
57
58
59
60

1
2
3 imaging, or self-report. Follow-up ranged from 48-150 days. Most studies provided reasons for
4 incomplete follow-up via a patient flow diagram.

7 **Respiratory Disease**

8
9 Five studies provided pulmonary outcomes (Supplemental Table 3).^{17-20,23} Two reported on baseline
10 COPD or current smoking status with 5-14% of COVID-19 patients (0%-12% of controls) having COPD
11 and 8-35% of COVID-19 patients (8-23% of controls) being current smokers.

12
13
14
15
16
17 Three large database studies reported incident respiratory disease. A UK study reported that patients with
18 COVID-19, at 146 days post-discharge, had significantly higher new onset respiratory disease (ICD-10
19 codes J00-99) (22% [6,085/28,335]) compared to general population, non-hospitalized controls (0.8%
20 [240/28,335]; $P < .001$).¹⁸ A US study, with over 54,000 records, reported a significantly increased odds
21 for new onset pneumonia at 1-30 days post-discharge in the COVID-19 group versus hospitalized non-
22 COVID controls (OR 5.5 [95%CI 4.1, 7.5]).¹⁹ The difference was no longer statistically significant at 31-
23 60, 61-90, and 91-120 days post-discharge. Similarly, patients with COVID-19 were more likely to have
24 “respiratory failure, insufficiency, or arrest” at 0-30 days post discharge as compared to non-COVID
25 controls (OR 3.3 [95%CI 2.6, 4.1]), but not at later follow-up. A US study, with over 36,000 records,
26 reported a higher incidence of the combined outcome of “overall respiratory failure at 4 months after
27 acute illness” in the COVID-19 group (2.6%) compared to non-COVID controls (0.2%) ($P < .001$).²⁰ A
28 higher incidence in the non-COVID-19 group was also noted for acute respiratory failure, chronic
29 respiratory failure, and interstitial lung disease.

30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45 Only one study reported pulmonary function tests and found no statistically significant difference among
46 COVID-19 cases (n=56) and non-hospitalized, non-COVID controls (n=30) in the percentage of
47 individuals having an abnormal (<80% predicted) FEV₁ (11% COVID-19, 0.4% control; $P = .42$) or FVC
48 (13% COVID-19, 0% control; $P = .09$) at 48 days post-discharge.²³

Measures of dyspnea were reported in 2 studies. Shortness of breath was greater in hospitalized US Veterans with COVID-19 (n=13,654) compared with historical controls hospitalized for seasonal influenza (n=13,997) (Hazard Ratio (HR) 1.14 [95%CI 1.04, 1.26]; excess burden per 1000 hospitalized at 6 months: 13.2 [95%CI 3.7, 21.9]).¹⁷ In another study “significant breathlessness” based on the mMRC dyspnea scale (<https://mrc.ukri.org/research/facilities-and-resources-for-researchers/mrc-scales/mrc-dyspnoea-scale-mrc-breathlessness-scale/>) was reported in 36/56 (64%) COVID-19 patients compared with 3/29 (10%) non-hospitalized, non-COVID cases at 48 days post-discharge.²³

Cardiovascular Outcomes

Five studies reported cardiovascular outcomes (Supplemental Table 3).^{17,18,20,22,25} Two reported presence of cardiovascular disease at baseline (3-13% of COVID-19 patients, 5-16% of controls) and 3 reported hypertension at baseline (15-52% of COVID-19 patients, 17-52% of controls).

Three large database studies reported diagnoses of cardiovascular disease following hospitalization for COVID-19. The study of over 27,000 Veterans reported greater incident acute coronary disease (HR 1.3 [95%CI 1.1, 1.5]) and heart failure (HR 1.2 [95%CI 1.03, 1.4]) for the COVID-19 group vs historical controls hospitalized with seasonal influenza during the 6 months following hospitalization.¹⁷

A second study from the US, including over 36,000 individuals in COVID-19 and concurrent non-COVID control groups, reported new cardiac diagnoses over 4 months follow-up.²⁰ Coronary disease (including myocardial infarction, acute coronary syndrome, and cardiogenic shock) was reported in 1.1% of the COVID-19 group and 0.2% of controls (P<.001). Congestive heart failure was reported in 1.5% of the COVID-19 group and 0.2% of controls (P<.001). Myocarditis incidence was rare and the difference between groups was not statistically significant (COVID-19: 0.09%, Control: 0.01%; P=1.0).

A study from the UK reported major adverse cardiovascular events (MACE) defined as heart failure, myocardial infarction, stroke, and arrhythmia, during a mean of 146 days post-discharge.¹⁸ New events

1
2
3 were reported in 2.6% (945/36,130) of the COVID-19 group and 0.5% (190/36,130) of the general
4
5 population control group ($P<.001$).
6
7

8 One smaller study used echocardiography to assess left ventricular ejection fraction at 48 days post-
9
10 discharge.²³ Left ventricular function was normal and comparable between the COVID-19 group and a
11
12 community dwelling non-COVID group.
13
14

15 Two studies used cardiovascular magnetic resonance imaging (CMR) to assess myocardial injury. In a
16
17 study from Germany, 100 patients (33 of whom had been hospitalized) were assessed at a median of 71
18
19 days following diagnosis.²² Late gadolinium enhancement (LGE), reflecting scarring, was observed in
20
21 32% (32/100) (myocardial) and 22% (22/100) (pericardial) of the COVID-19 group. Myocardial LGE
22
23 was significantly more prevalent ($P<.05$) in COVID-19 patients than in healthy controls (0%) or risk
24
25 factor-matched controls (17% (9/57)). Pericardial LGE was significantly more prevalent ($P<.05$) in
26
27 COVID-19 patients than in healthy controls (0%) but not risk factor-matched controls (14% (8/57)).
28
29
30

31 A second study assessed outcomes at a median of 48 days post-discharge. LGE (myocarditis pattern) was
32
33 observed in 12% (6/52) of the COVID-19 group (moderate to severe disease) and 7% (2/28) of
34
35 community-dwelling, non-COVID controls ($P=.47$).
36
37

38 The studies also reported on presence of pericardial effusion based on CMR. The study from Germany
39
40 reported pericardial effusion (>10 mm) in 20% (20/100) of COVID-19 patients, 0% of healthy controls,
41
42 and 7% (4/57) of risk factor-matched controls ($P<0.05$ for the COVID-19 group vs each control group) at
43
44 a median of 71 days following diagnosis.²² The other study reported pericardial effusion (>10 mm) in 2%
45
46 (1/52) of the COVID-19 group and 0% (0/28) of community dwelling, non-COVID controls at a median
47
48 of 48 days post-discharge.²³
49
50

51
52 The CMR study from Germany²² reported detectable high-sensitivity troponin T (hsTNT) (>3 pg/mL) in
53
54 71% (71/100) of the COVID-19 group, with significantly elevated hsTNT (>13.9 pg/mL) in 5% (5/100) at
55
56
57

1
2
3 a median of 71 days following diagnosis. The percentage of patients with detectable hsTNT was
4 significantly higher ($P<.05$) in the COVID-19 group than in healthy (22% [11/50] or risk factor-matched
5 controls (54% [31/57]). The second study, with a control group of non-COVID-19 community members
6 reported no cases of abnormal troponin T in either the COVID-19 or control groups at a median of 48
7 days post-discharge.²³

13 **Neurologic and Cognitive Outcomes:**

14 Neurologic and cognitive outcomes were reported by 4 studies (Supplemental Table 3).^{17,19,20,23}

15
16 The study of over 27,000 US Veterans reported an increased risk of stroke 6 months after hospitalization
17 for COVID-19 among individuals without a history of stroke in the past year, as compared to historical,
18 matched controls with seasonal influenza (HR 1.30; 95%CI 1.05, 1.60).¹⁷ Another US study reported the
19 prevalence of new onset stroke during the 4 months post-hospitalization.²⁰ Ischemic and hemorrhagic
20 stroke was reported in 1.1% of the COVID-19 group and 0.3% of matched non-COVID controls (risk
21 difference 0.8% [95%CI 0.4, 1.2], $P<.001$).

22
23 For incident neurocognitive disorders, US Veterans hospitalized for COVID-19 had an excess burden per
24 1000 COVID-19 persons at 6 months of 16.2 (95%CI 10.4, 21.2) compared to hospitalized seasonal
25 influenza cases.¹⁷ In another database study, neurocognitive disorders, defined using the Clinical
26 Classification Software Refined (CCSR) categories, were more likely in patients hospitalized with
27 COVID-19 vs non-COVID controls (OR 1.6 [95%CI 1.2, 2.1]) in the first 30 days after discharge but not
28 at 60, 90 or 120 days.¹⁹

29
30 In a US database study enrolling adults age 18-65 years, newly diagnosed dementia through 120 days
31 post-acute infection was greater in the COVID-19 group compared to non-COVID controls (0.2% vs.
32 0.03%; risk difference 0.2% [95%CI 0.7, 0.3], $P<.001$).²⁰ In the same study, Alzheimer-type dementia
33 was noted in 0.04% of the COVID-19 group and 0% of controls ($P<.001$).

1
2
3 One study reported Montreal Cognitive Assessment (MoCA) scores of less than 26 (ie, cognitive
4 impairment) in 28% of the COVID-19 group and 17% of community-based controls (P=.30) at a median
5 of 48 days post-discharge.²³
6
7

8 **Renal Outcomes**

9
10 Renal outcomes were reported by 6 studies (Supplemental Table 3).^{17-21,23} A history of chronic kidney
11 disease (CKD) at baseline was reported in 2 studies - 13% of patients in both the COVID-19 and the
12 control groups in one study¹⁸ and 33% of the COVID-19 group and 35% of controls in the other.²¹
13
14 CKD, identified by ICD-10 codes, was reported in 3 large database studies.^{17,18,20} In the study of US
15 Veterans, the HR for a new diagnosis of CKD during the 6 months after acute infection in the COVID-19
16 group vs seasonal influenza controls was 1.4 (95%CI 1.1, 1.7).¹⁷ A second US study, with data from over
17 36,000 individuals, reported new diagnoses of CKD (all stages) at 4 months after acute illness in 2.1% of
18 the COVID-19 group and 0.7% of non-COVID controls (P<.001).²⁰ The third study, completed in the UK,
19 included data from over 82,000 individuals and reported new onset CKD stages 3-5 in 0.6% of the
20 COVID-19 group and 0.3% of general population controls at a mean of approximately 146 days post-
21 discharge.¹⁸
22
23
24
25
26
27
28
29
30
31
32
33

34
35 A new diagnosis of acute kidney injury (AKI) following discharge was reported in 3 large data base
36 studies.^{17,19,20} The study of US Veterans, reported an adjusted HR for AKI during the 6 months following
37 COVID-19 infection for the COVID-19 group vs seasonal influenza controls (HR 1.2 [95%CI 1.1, 1.4]).¹⁷
38 A second US study reported ORs for “acute and unspecified kidney failure” vs hospitalized non-COVID-
39 19 controls.¹⁹ ORs decreased from 1.3 (95%CI 1.0, 1.6) at 30 days post-discharge to 0.6 (95%CI 0.4, 0.8)
40 at 120 days post-discharge. The third study, also from the US, reported a new diagnosis of AKI during the
41 4 months after acute infection in 2.9% of the COVID-19 group and 0.5% of non-COVID controls
42 (P<.001).²⁰
43
44
45
46
47
48
49
50
51
52

53 In a study of patients with COVID-19 associated AKI, defined as >50% increase in creatinine over
54 baseline or 0.3mg/dl increase over lowest level at 48 hours, and a control group with non-COVID
55
56
57

1
2
3 associated AKI, the COVID-19 group demonstrated lower rates of AKI recovery post hospital discharge
4
5 (HR_{adj} 0.57 [95% CI 0.35, 0.92]; P=.02).²¹
6

7 **Endocrine**

8
9 Three database studies, 2 from the US^{17,20} and 1 from the UK,¹⁸ reported the presence of diabetes
10
11 (Supplemental Table 3). Diabetes at baseline was reported in one study (24%).¹⁸ A US study, with data
12
13 from over 27,000 Veterans without a history of diabetes in the previous year, reported greater risk for
14
15 diabetes in the COVID-19 group than in a matched, seasonal influenza controls (HR 1.6 [95%CI 1.4,
16
17 1.9]).¹⁷ The excess burden per 1000 hospitalized COVID-19 patients was 21.4 (95%CI 15.1, 26.8) at 6
18
19 months following COVID-19 infection. The second US study included over 36,000 hospitalized patients
20
21 in COVID-19 and matched non-COVID-19 groups. Through 4 months after acute illness, a new clinical
22
23 diagnoses of Type 2 diabetes was reported in 3% of the COVID-19 group and 0.8% of controls (risk
24
25 difference 2.2% [95%CI 1.4, 3.2]).²⁰
26
27

28
29 The UK study, with data from over 72,000 individuals (COVID-19 and a matched, general population
30
31 controls) reported new onset Type 1 diabetes, during a mean of approximately 146 days after discharge,
32
33 in 1.1% (400/36,100) of the COVID-19 group and 0.3% (125/36,100) of controls.¹⁸ Rates per 1000
34
35 person-years were 28.7 for the COVID-19 group and 8.2 for controls.
36
37

38 **Gastrointestinal Outcomes**

39
40 Three studies reported gastrointestinal outcomes (Supplemental Table 3).^{17,18,20} Two database studies
41
42 identified gastrointestinal disease using ICD-10 codes.^{17,18} The study of Veterans identified incidence of
43
44 gastrointestinal disorders (*eg*, dysphagia) in over 27,000 individuals hospitalized for either COVID-19 or
45
46 seasonal influenza.¹⁷ During 6 months follow-up, the excess burden per 1000 COVID-19 persons was
47
48 19.3 (95%CI 12.8, 25.1). The second study, from the UK (46,395 matched pairs), identified new onset
49
50 chronic liver disease over a mean follow-up of 140 days among individuals hospitalized with COVID-19
51
52 (0.2% [70/46,395]) compared to a non-hospitalized general population (0.04% [15/46,395]).¹⁸ The
53
54 difference was statistically significant (P<.001). The third study, enrolling over 18,000 matched pairs,
55
56
57

1
2
3 reported liver test abnormalities at 4 months after acute illness in 3.3% of the COVID-19 group and 1.4%
4
5 of the control group ($P<.001$).²⁰
6

7 **Hematologic Outcomes**

8
9 Three studies reported venous thromboembolism (VTE) outcomes post-discharge (Supplemental Table
10 3).^{17,19,20} A US study, including data from over 54,000 individuals, reported ORs for acute pulmonary
11 embolism (PE) vs non-COVID controls of 1.5 (95%CI 1.0, 2.1) at 30 days post-discharge and 1.4 (95%CI
12 0.9, 2.1) at 60 days. ORs at 90 and 120 days were also not statistically significant.¹⁹ Another US study,
13 with data from over 36,000 individuals, reported PE in 1.3% of the COVID-19 group and 0.1% of the
14 non-COVID controls through 120 days post-infection.²⁰ Deep venous thrombosis was reported in 2.3% of
15 the COVID-19 group and 0.3% of controls. The study of over 27,000 US Veterans observed an excess
16 burden for PE per 1000 COVID-19 persons (vs seasonal influenza controls) of 18.3 (95%CI 15.8, 20.3)
17 and an HR for thromboembolism of 2.3 (95%CI 1.9, 2.6) through 150 days post-discharge.¹⁷
18
19

20
21 The same studies reported coagulation disorders (with varying definitions of “coagulation” between
22 studies). The study of over 27,000 US Veterans reported an excess burden of coagulation (defined by
23 ICD-10 codes, not specified) per 1000 COVID-19 persons of 14.3 (95%CI 10.1, 17.9) compared to a
24 seasonal influenza controls.¹⁷ Another US study reported a higher risk of hypercoagulability (ICD-10
25 codes D68 and I82) in the COVID-19 group (3.2%) than in non-COVID controls (0.4%) during the 4
26 months after acute illness.²⁰ The risk difference was 2.8 (95%CI 2.3, 3.6) ($P<.001$). The third study, also
27 from the US, reported odds ratios (COVID-19 vs hospitalized non-COVID-19 controls) for the overall
28 category of coagulation and hemorrhagic disorders.¹⁹ The ORs at 30, 60, 90, and 120 days were 1.3
29 (95%CI 1.0, 1.6), 1.3 (95%CI 0.95, 1.7), 0.65 (95%CI 0.5, 0.9), and 0.66 (95%CI 0.5, 0.97), respectively.
30
31 It was noted that the top 5 coagulation and hemorrhagic disorders were “unspecified thrombocytopenia,
32 other primary thrombophilia, other secondary thrombocytopenia, unspecified coagulation defect, and
33 other thrombophilia”.
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

CONCLUSIONS

Key Findings

Our review of COVID-19 post-acute major organ damage found that incident respiratory disease may be higher in post-hospitalization COVID-19 cases as compared to non-COVID controls. Prevalence ranged from 2% to 22% in COVID-19 groups compared to less than 1% in controls. Dyspnea was much more prevalent (64% vs 10%) and there was greater risk for dyspnea in COVID-19 groups than in controls.

Patients with COVID-19 were also at greater risk for incident cardiovascular disease outcomes (including acute myocardial infarction, coronary disease, heart failure) compared to controls. Prevalence of new cardiovascular events ranged from approximately 1 to 3% in the COVID-19 groups and less than 1% in controls. Myocardial inflammation/fibrosis was more prevalent in COVID-19 patients than controls.

Myocarditis was rare.

Among other organ systems, the prevalence, or risk for, stroke, new onset chronic kidney disease, acute kidney injury, new onset diabetes, incident gastrointestinal disorders, and new onset chronic liver disease was higher in COVID-19 groups than in matched controls. The incidence of dementia post COVID-19 was low but may exceed that of non-COVID cases. The prevalence of, or risk for, coagulation and hemorrhagic disorders was higher in COVID-19 groups than in control groups though disorder definitions were unclear and varied.

Limitations of the evidence exist. Although evidence includes 4 large database studies with controls, most data, cited in the living review, are from small single center convenience sample studies with poorly described populations or measures of major organ damage. Among the 9 studies with controls cited in this manuscript, control groups varied. Three studies included historical controls and 6 included concurrent controls. In 4 of the concurrent control studies, control group patients were not hospitalized. Reported prevalence rates are likely highly dependent on pre-existent demographics and comorbidities of the study population, COVID-19 disease severity, the measures used to assess and define major organ damage, and

1
2
3 the timing of assessment relative to hospital discharge. Follow-up times for the 9 studies with control
4 groups ranged from 30 to 150 days. Long-term major organ damage (ie, ≥ 6 months) prevalence remains
5 unknown. There are no data reporting on outcomes based on patient living situation prior to COVID-19
6 infection (ie, community dwelling versus nursing home or assisted care centers). No data exist to
7 ascertain if outcomes differ based on COVID-19 vaccination status or with infection with different
8 COVID-19 variants, especially the delta variant. Disease diagnosis relied on clinician coding rather than a
9 standardized physiologic/laboratory value. There are also limitations of our review methods. We defined
10 “post-acute COVID” as post-hospital discharge. The applicability of these findings to non-hospitalized
11 patients with acute COVID symptoms is unclear.

12
13 We are aware of several systematic reviews reporting persistent symptoms following recovery from acute
14 COVID-19.²⁶⁻³⁰ Fatigue, dyspnea, chest pain, sleep disorders, cognitive impairment, and difficulty
15 concentrating are commonly reported symptoms. Our review complements these reviews by focusing on
16 1) patients requiring hospitalization for laboratory-confirmed COVID-19, 2) major organ damage from all
17 organ systems rather than symptoms, and 3) controlled studies.

18
19 In conclusion, post-acute COVID-19 major organ damage following hospitalization for COVID-19
20 infection is common and likely higher than non-COVID controls. However, there is substantial
21 uncertainty due to evidence limitations. More consistent reporting of clinically relevant outcomes and pre-
22 COVID health status as well as use of appropriately matched controls is needed to address evidence gaps.

Contributors:

Conception/design: NG, BB, CJB, SJD, KEE, AK, MK, ACM, SR, AS, KS, JS, OV, WD-P, TJW

Acquisition, analysis, or interpretation of data: NG, BB, CJB, SJD, KEE, AK, MK, ACM, SR, AS, KS, JS, OV, LM, BS, RM, KS, WD-P, TJW

First draft of the manuscript: NG, TJW

Manuscript drafting, revision, approval: NG, BB, CJB, SJD, KEE, AK, MK, ACM, SR, AS, KS, JS, OV, LM, BS, RM, KS, WD-P, TJW

Overall guarantors: NG, TJW

Funding: This work was supported by the Department of Veterans Affairs, Veterans Health

Administration, Health Services Research and Development, Evidence Synthesis Program, Grant #09-009

Ethics Approval: This study does not involve human participants. This study does not involve animal subjects.

Competing Interests: None declared

Data Sharing: All data are available in Supplemental Tables 2 and 3.

REFERENCES

1. Gupta A, Madhavan MV, Sehgal K, et al. Extrapulmonary manifestations of COVID-19. *Nat Med*. 2020;26(7):1017-1032.
2. Mitrani RD, Dabas N, Goldberger JJ. COVID-19 cardiac injury: Implications for long-term surveillance and outcomes in survivors. *Heart Rhythm*. 2020;17(11):1984-1990.
3. Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. *Nat Med*. 2021;27(4):601-615.
4. Chen YT, Shao SC, Hsu CK, Wu IW, Hung MJ, Chen YC. Incidence of acute kidney injury in COVID-19 infection: a systematic review and metaanalysis. *Crit Care*. 2020;24(1):346.
5. Hirsch JS, Ng JH, Ross DW, et al. Acute kidney injury in patients hospitalized with COVID-19. *Kidney Int*. 2020;98(1):209-218.
6. Varatharaj A, Thomas N, Ellul MA, et al. Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study. *Lancet Psychiatry*. 2020;7(10):875-882.
7. Korolnik IJ, Tyler KL. COVID-19: A global threat to the nervous system. *Ann Neurol*. 2020;88(1):1-11.
8. Bikdeli B, Madhavan MV, Jimenez D, et al. COVID-19 and thrombotic or thromboembolic disease: Implications for prevention, antithrombotic therapy, and follow-up. *J Am Coll Cardiol*. 2020;75(23):2950-2973.
9. Bilaloglu S, Aphinyanaphongs Y, Jones S, Iturrate E, Hochman J, Berger JS. Thrombosis in hospitalized patients with COVID-19 in a New York City Health System. *JAMA*. 2020;324(8):799-801.
10. Connors J, Levy J. COVID-19 and its implications for thrombosis and anticoagulation. *Blood*. 2020;135(23):2033-2040.
11. Rubino F, Amierl SA, Zimmet P, et al. New-onset diabetes in Covid-19. *N Engl J Med*. 2020;383(8):789-790.
12. Hajifathalian K, Krisko T, Mehta A, et al. Gastrointestinal and hepatic manifestations of 2019 novel coronavirus disease in a large cohort of infected patients from New York: Clinical implications. *Gastroenterology*. 2020;159(3):1137-1140.
13. Renu K, Prasanna PL, Gopalkrishnan AV. Coronaviruses pathogenesis, comorbidities and multi-organ damage – A review. *Life Sci*. 2020;255:117839.
14. Ahmed H, Patel K, Greenwood D, et al. Long-term clinical outcomes in survivors of coronavirus outbreaks after hospitalisation or ICU admission: A systematic review and meta-analysis. *J Rehabil Med*. 2020;52(5):jrm00063.
15. Prescott HC, Girard TD. Recovery from severe COVID-19: Leveraging the lessons of survival from sepsis. *JAMA*. 2020;324(8):739-740.
16. Moola S, Munn Z, Tufanaru C, et al. Chapter 7: Systematic reviews of etiology and risk. In: Aromataris E, Munn Z, eds. *JBIM Manual for Evidence Synthesis*, 2020.
17. Al-Aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19. *Nature*. 2021;594(7862):259-264.
18. Ayoubkhani D, Khunti K, Nafilyan V, et al. Post-covid syndrome in individuals admitted to hospital with covid-19: retrospective cohort study. *BMJ*. 2021;372:n693.
19. Chevinsky JR, Tao G, Lavery AM, et al. Late conditions diagnosed 1-4 months following an initial COVID-19 encounter: a matched cohort study using inpatient and outpatient administrative data - United States, March 1-June 30, 2020. *Clin Infect Dis*. 2021;73:S5-S16.
20. Daugherty SE, Guo Y, Heath K, et al. Risk of clinical sequelae after the acute phase of SARS-CoV-2 infection: retrospective cohort study. *BMJ*. 2021;373:n1098.

21. Nugent J, Aklilu A, Yamamoto Y, et al. Assessment of acute kidney injury and longitudinal kidney function after hospital discharge among patients with and without COVID-19. *JAMA Netw Open*. 2021;4(3):e211095.
22. Puntmann VO, Carerj ML, Wieters I, et al. Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19). *JAMA Cardiol*. 2020;5(11):1265-1273.
23. Raman B, Cassar MP, Tunnicliffe EM, et al. Medium-term effects of SARS-CoV-2 infection on multiple vital organs, exercise capacity, cognition, quality of life and mental health, posthospital discharge. *EClinicalMedicine*. 2021;31:100683.
24. Roberts LN, Whyte MB, Georgiou L, et al. Postdischarge venous thromboembolism following hospital admission with COVID-19. *Blood*. 2020;136(11):1347-1350.
25. Xiong Q, Xu M, Li J, et al. Clinical sequelae of COVID-19 survivors in Wuhan, China: a single-centre longitudinal study. *Clin Microbiol Infect*. 2021;27(1):89-95.
26. Groff D, Sun A, Ssentongo AE, et al. Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection: a systematic review. *JAMA Netw Open*. 2021;4(10):e2128568.
27. Michelen M, Manoharan L, Elkheir N, et al. Characterising long COVID: a living systematic review. *BMJ Glob Health*. 2021;6(9):e005427.
28. Nasserie T, Hittle M, Goodman SN. Assessment of the frequency and variety of persistent symptoms among patients with COVID-19: A systematic review. *JAMA Netw Open*. 2021;4(5):e2111447.
29. van Kessel SAM, Olde Hartman TC, Lucassen PLBJ, van Jaarsveld CHM. Post-acute and long-COVID-19 symptoms in patients with mild diseases: a systematic review. *Fam Pract*. 2021:cmab076.
30. Cabrera Martimbianco AL, Pacheco RL, Bagattini AM, Riera R. Frequency, signs and symptoms, and criteria adopted for long COVID-19: A systematic review. *Int J Clin Pract*. 2021;75(10):e14357.


Table 1. Study Eligibility Criteria

Study Characteristic	Include	Exclude
Population	Adults (age 18 and older); at least 50 case patients for manuscript	Children or adolescents, age <18; MERS; SARS
Intervention	Discharge from hospitalization after admission with or for proven COVID-19 ^a	Data only collected from patients during ongoing hospital acute-care admission with or for proven COVID-19
Comparator	Discharge from hospitalization for individuals without COVID-19 (ideally another respiratory condition); a comparator was not required for the living review but only studies with a control group are included in the manuscript	Not applicable
Outcomes	Prevalence and severity of major organ damage (respiratory, renal, cardiovascular, hematologic, neurologic and cognitive, endocrine, gastrointestinal, and hematologic); healthcare or service use needs related to major organ damage ^b	No outcomes of interest
Timing	Short-term (< 3 months) and long-term (≥ 3 months) post-discharge	Not applicable
Setting	Any post-discharge setting (eg, home, rehabilitation or long-term care facility); may include re-hospitalization	Not applicable
Study Designs	Cohort, case series, other observational; may prioritize articles using a best-evidence approach	Case report, narrative review, descriptive/opinion article with no data

^aIn the original and first update of the living review, we reported outcomes at the time of discharge. For the September 2021 update and this manuscript, patients must be discharged with post-discharge outcome data available.

^bIn the original version of the living review, we included studies reporting “re-positive” RT-PCR test results following discharge. For the June 2021 update and later versions, we excluded studies only reporting “re-positive” test results and removed those studies from the original set of included studies. As more information about the natural history of SARS-CoV-2 has become available, it has been recognized that patients may be PCR positive for prolonged periods after an initial COVID illness, and an isolated PCR positivity in such patients (especially for the first 90 days after diagnosis) does not by itself reflect a new infection. Healthcare or service use needs outcomes are not reported in the manuscript.

Figure. Literature Flow Diagram



Supplemental Table 1. MEDLINE/EMBASE Search Strategy

1	(coronavir* or corona virus* or betacoronavir* or covid19 or covid 19 or nCoV or CoV 2 or CoV2 or sarscov2 SARS 2 or SARS-CoV-2 or 2019nCoV or 2019 novel coronavirus* or 2019 novel CoV or wuhan virus* or ((wuhan or hubei or huanan) and (severe acute respiratory or pneumonia*))).ti,ab,kw.
2	Coronavirus Infections/ or Coronavirus/ or betacoronavirus/
3	1 or 2
4	Pulmonary fibrosis.ti,ab,kw. or exp Pulmonary Fibrosis/
5	exp Lung Diseases, Obstructive/
6	4 or 5
7	acute kidney injury.ti,ab,kw. or exp Acute Kidney Injury/
8	exp Renal Insufficiency, Chronic/
9	(end stage renal disease or ESRD or AKI or CKD).ti,ab,kw.
10	7 or 8 or 9
11	myocardial infarction.ti,ab,kw. or exp Myocardial Infarction/
12	(heart attack or heart failure or MI).ti,ab,kw.
13	myocarditis.ti,ab,kw. or exp Myocarditis/
14	exp Arrhythmias, Cardiac/
15	arrhythmia*.ti,ab,kw.
16	11 or 12 or 14 or 14 or 15
17	exp Venous Thrombosis/
18	exp Pulmonary Embolism/ or exp Venous Thromboembolism/
19	(deep ve* thrombosis or DVT or pulmonary embolism or PE).ti,ab,kw.
20	anemia.ti,ab,kw. or exp Anemia/
21	17 or 18 or 19 or 20
22	stroke.ti,ab,kw. or exp Stroke/
23	exp Cognitive Dysfunction/
24	exp Confusion/
25	exp Seizures/
26	exp Headache/
27	(stroke* or cerebrovascular accident* or cognitive impairment or cognitive dysfunction or delirium or confusion or seizure* or headache*).ti,ab,kw.
28	22 or 23 or 24 or 25 or 26 or 27
29	exp Diabetes Mellitus/
30	diabetes.ti,ab,kw.
31	29 or 30
32	exp Hepatitis/
33	exp Colitis/
34	(hepatitis or hepatocellular injur* or colitis).ti,ab,kw.
35	32 or 33 or 34
36	"Autoimmune Diseases of the Nervous System"/
37	autoimmune disease*.ti,ab,kw.
38	Musculoskeletal Diseases/
39	musculoskeletal.ti,ab,kw.
40	36 or 37 or 38 or 39
41	6 or 10 or 16 or 21 or 28 or 31 or 35 or 40
42	exp Hospitalization/ or exp Intensive Care Units/ or Inpatients/ or Subacute Care/
43	(hospital or hospitalized or hospitalization or intensive or ICU or care or post?acute or inpatient or inpatients or admit or admitted or admitting).ti,ab,kw.
44	42 or 43
45	3 and 41 and 44
46	limit 45 to english language
47	limit 46 to yr="2019 -Current"

Supplemental Table 2. Study Characteristics for Studies with Control Groups

Author, Year Country Study Design Funding	Inclusion/Exclusion Criteria	Baseline Demographic Data	Hospitalization Characteristics Time of Post-hospital Follow-up
Al-Aly, 2021(1) USA (Veterans) Retrospective Funding: VA	Inclusion: Admitted for COVID-19 within 30 days after or 5 days before first positive test and survived at least 30 days after hospital admission; selected from 98,661 patients with positive COVID-19 test between March 01, 2020 and November 30, 2020 Exclusion: None specified Controls: hospitalized for seasonal influenza between October 01, 2016 and February 29, 2020; survived 30 days after hospital admission Propensity scores based on predefined variables were estimated to adjust for potential confounders	N=13,654 (COVID-19 group); N=13,997 (Control group) Age (years, mean): 70 (COVID-19 and Control groups) Gender (% male): 94 (COVID-19 and Control groups) Race/ethnicity: COVID-19 group: White 59%, Black 34%; Control group: White 73%, Black 22% Comorbidities: NR	COVID-19 severity: NR ICU admission: 26% (n=3586) Respiratory support Mechanical ventilation or ECMO: NR NIV, HFNC, or CPAP: NR Other: NR Length of hospital stay: NR Planned time post-hospital in patients that survived 30 days after diagnosis (days): 180 Reported time post-hospital (days, median): COVID-19 group: 150, Control group: 157
Ayoubkhani, 2021(2) United Kingdom Retrospective Funding: none	Inclusion: Hospitalized for COVID-19, (positive laboratory test or clinical diagnoses) from January 1, 2020 to end of August 2020 Exclusion: Not discharged alive by August 31, 2020 or birth date or gender unknown Controls: individuals in general population, did not meet inclusion criteria for COVID-19, and had not died before January 1, 2020; 79% had prior hospital admission	N=47,780 (for both COVID-19 group and matched control group) Age (%): COVID-19 group Age <30: 5; 30-49: 16; 50-69: 33; ≥70: 46 Control group <30: 3; 30-49: 19; 50-69: 33; ≥70: 46 Gender (% male): 55 (COVID-19 and Control groups) Race/ethnicity: White 72%, Asian 9%, Black 5% (COVID-19 and Control groups) Comorbidities:	COVID-19 severity: NR ICU admission: 10% (n=4745) Respiratory support: NR Length of hospital stay: NR Planned time post-hospital: NR Reported time post-hospital (days, mean): COVID-19 group: 140, Control group: 153

136/bmjopen-2022-012418 on 24 August 2022. Downloaded from <http://bmjopen.bmj.com/> by guest. Protected by copyright.

Author, Year Country Study Design Funding	Inclusion/Exclusion Criteria	Baseline Demographic Data	Hospitalization Characteristics Time of Post-hospital Follow-up
Chevinsky 2021(3) USA Retrospective Funding: Not reported	<p>Patients and controls matched (1:1) on several confounding variables; all were active patients in National Health Service</p> <p>Inclusion: Hospitalized for COVID-19 (ICD-10 code) from March 1 to June 30, 2020</p> <p>Exclusion: Patients with at least 1 encounter preceding index encounter or who died or were pregnant in index encounter</p> <p>Controls: hospitalized individuals who did not meet inclusion criteria for COVID-19 and were not diagnosed with COVID-19 during the 4 months after index encounter</p> <p>Patients and controls matched (1:1) based on propensity scores on several confounding variables</p>	<p>MACE: 24% (COVID-19 and Control groups) CKD: 13% (COVID-19 and Control groups) COPD: COVID-19 group: 14%; Control group: 12% DM: 24% (COVID-19 and Control groups) HTN: 52% (COVID-19 and Control groups) Obesity (BMI ≥30): 32% (COVID-19 and Control groups) Smoking: 8% current, 41% former (COVID-19 and Control groups)</p> <p>N=27,284 adults for both COVID-19 and Control groups Age (%): COVID-19 group Age 18-39: 9; 40-49: 10; 50-64: 28; ≥65: 53 Control group Age 18-39: 11; 40-49: 9; 50-64: 27; ≥65: 54 Gender (% male): COVID-19 group: 48; Control group: 47 Race/ethnicity: COVID-19 group: White 48%, Black 26%, Asian 2%, Hispanic 13% Control group: White 47%, Black 26%, Asian 2%, Hispanic 14%</p> <p>Comorbidities: NR</p>	<p>COVID-19 severity: NR</p> <p>ICU admission: both groups 40%</p> <p>Respiratory support: NR</p> <p>Length of hospital stay (days, median): COVID-19 group 6 (range 3, 11); Control group 4 (range 2, 6)</p> <p>Planned time post-hospital (days): 30-120</p> <p>Reported time post-hospital (days): NR</p>
Daugherty 2021(4) USA	Inclusion: Ages 18-65 diagnosed with COVID-19 (SARS-CoV-2); continuous enrollment in the health plan from January	N=21,746 hospitalized (N=18,118 for both COVID-19 and control groups in matched analysis after	COVID-19 severity: NR ICU admission: 13% (n=2933)

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

Author, Year Country Study Design Funding	Inclusion/Exclusion Criteria	Baseline Demographic Data	Hospitalization Characteristics Time of Post-hospital Follow-up
Retrospective Funding: Insurance (Research & Development)	<p>1, 2019 to index date (defined by first of: 1) primary, secondary, or tertiary diagnosis of COVID-19; 2) administrative claims with ICD-10 codes U07.1 or either B34.2 or B97.29 before April 1, 2020; 3) documentation of positive PCR test in outpatient laboratory dataset; or 4) admitted to hospital for COVID-19 (based on diagnostic code))</p> <p>Exclusion: Positive SARS-CoV-2 antibodies but without documented infection; ICD-10 codes B34.2 or B97.29 on or after April 1, 2020; and admitted to hospital for suspected COVID-19 but missing diagnostic codes</p> <p>Controls: ages 18-65 without COVID-19 (SARS-CoV-2) diagnosis with continuous health plan enrollment from January 1 2019 to randomly assigned month and day drawn from the SARS-CoV-2 infection group (2020 comparator group used for analysis of hospitalized patients)</p> <p>Patients and controls matched (1:1) using propensity scores based on 108 variables</p>	<p>exclusion if less than index date + 21 days of follow-up); demographics and comorbidities NR for hospitalized subgroup Age (years, mean): NR Gender (% male): NR Race/ethnicity: NR</p> <p>Comorbidities: NR</p>	<p>Respiratory support: NR Length of hospital stay: NR Planned time to <u>post-acute infection*</u> (days): 90-180 Reported time to <u>post-acute infection*</u> (days, mean): 120 NOTE: post-acute infection defined as index date plus 21 days</p>
Nugent, 2021(5) USA Retrospective Funding: Foundation	<p>Inclusion: Tested for COVID-19 by RT-PCR, developed AKI during hospitalization, survived past discharge, did not require dialysis within 3 days of discharge, had ≥1 measurement of serum creatinine as an outpatient post-discharge</p>	<p>N=1612 (182 COVID-19) Age (years, median): 70 (67 COVID-19 group) Gender (% male): 50 (53 COVID-19 group) Race/ethnicity: 40% Black, 41% White, 3% Asian, 17% Other; 22% Hispanic (COVID-19 group)</p>	<p>COVID-19 severity: NR ICU admission: 37% (COVID-19 group) Respiratory support Mechanical ventilation or ECMO: 29% (COVID-19 group)</p>

136/bmjopen-2022-012159 on 24 August 2023. Downloaded from <http://bmjopen.bmj.com/> on April 18, 2024 by guest. Protected by copyright.

136/bmjopen-2022-012129 on 24 August 2022. Downloaded from <http://bmjopen.bmj.com/> by guest. Protected by copyright.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Author, Year Country Study Design Funding	Inclusion/Exclusion Criteria	Baseline Demographic Data	Hospitalization Characteristics Time of Post-hospital Follow-up
Puntmann, 2020(6) Germany Prospective Funding: Government, Industry, Institution	<p>Exclusion: Age <18 years, determined to have ESKD, received prior kidney transplant, initial creatinine level ≥4 mg/dL</p> <p>Controls: hospitalized patients with AKI and negative test for COVID-19</p> <p>Inclusion: Minimum of 2 weeks post-diagnosis of SARS-CoV-2 by RT-PCR; resolution of respiratory symptoms; negative results on swab test at end of isolation period</p> <p>Exclusion: Recently recovered from COVID-19 and referred for clinical CMR imaging; unwilling to participate; absolute contraindications for contrast-enhanced magnetic resonance study</p> <p>Controls: healthy and risk-factor matched groups</p>	<p>Comorbidities: CVD: NR CKD: 35% (33% COVID-19 group) COPD: 47% (45% COVID-19 group) DM: 52% (64% COVID-19 group) HTN: 89% Obesity: NR Smoking: NR</p> <p>N=100 Age (years, mean): 49 Gender (% male): 53 Race: NR</p> <p>Comorbidities: CVD: 13% CKD: NR COPD: 21% DM: 18% HTN: 22% Obesity: NR Smoking: 22%</p>	<p>NIV, HFNC, or CPAP: NR Other: NR</p> <p>Length of hospital stay (days, mean): 14 (COVID-19 group)</p> <p>Planned time post-hospital: NR</p> <p>Reported time post-hospital (days, median): 93 (COVID-19 group)</p> <p>COVID-19 severity: 18% asymptomatic, 49% mild/moderate (both recovered at home), 33% severe (required hospitalization)</p> <p>ICU admission: NR</p> <p>Respiratory support Mechanical ventilation or ECMO: 2%, 6% (hospitalized group) NIV, HFNC, or CPAP: 17%, 52% (hospitalized group) Other: 28% (NR for hospitalized group)</p> <p>Length of hospital stay: NR</p> <p>Planned/reported time post-hospital: NR</p> <p>NOTE: median time from diagnosis to CMR was 71 [IQR 64-92] days)</p>

Author, Year Country Study Design Funding	Inclusion/Exclusion Criteria	Baseline Demographic Data	Hospitalization Characteristics Time of Post-hospital Follow-up
Raman, 2021(7) United Kingdom Prospective Funding: Government, Foundation	<p>Inclusion: All patients with moderate to severe laboratory COVID-19 (positive SARS-CoV-2)</p> <p>Exclusion: Severe comorbidities (end-stage renal, cardiac, liver, or neurological disease), contradictions to MRI</p> <p>Controls: uninfected (negative for SARS-CoV-2 and asymptomatic), from the community (not hospitalized), group-matched for age, sex, body mass index, and risk factors</p>	<p>N=58 COVID-19</p> <p>Age (years, mean): 55</p> <p>Gender (% male): 59</p> <p>Race/ethnicity: 22% Black/Asian and minority ethnic groups; 78% White</p> <p>Comorbidities: CAD: 3% CKD: NR COPD: 5% DM: 16% (Type 1 and 2) HTN: 38% Obesity: NR Smoking: 35% Current or ex-smoker</p>	<p>COVID-19 severity: Moderate to severe (inclusion criteria)</p> <p>ICU admission: 36% (21/58)</p> <p>Respiratory support Mechanical ventilation or ECMO: 21% NIV, HFNC, PAP: 26% Other: 46%</p> <p>Length of hospital stay (days, median): 8.5</p> <p>Planned time post-hospital (days): 30-180</p> <p>Reported time post-hospital (days, median): 48</p>
Roberts, 2020(8) United Kingdom Prospective Funding: Not reported	<p>Inclusion: Patients discharged following admission for COVID-19; 6-week follow-up for hospital-associated VTE (HA-VTE) events</p> <p>Exclusion: None reported</p> <p>NOTES: 1) patients received thromboprophylaxis while hospitalized</p> <p>Controls: cohort of post-discharge HA-VTE following medical admission in 2019</p>	<p>N=1877</p> <p>Age (years, mean): NR</p> <p>Gender (% male): NR</p> <p>Race: NR</p> <p>Comorbidities: NR</p>	<p>COVID-19 severity: NR</p> <p>ICU admission: NR (11% [208/1877] admitted to critical care)</p> <p>Respiratory support: NR</p> <p>Length of hospital stay: NR</p> <p>Planned/reported time post-hospital (days): 90</p>

136/bmjopen-2022-012150 on August 18, 2024. Protected by copyright.

136/bmjopen-2022-012124 on 18 August 2022. Downloaded from <http://bmjopen.bmj.com/> on April 18, 2024 by guest. Protected by copyright.

Author, Year Country Study Design Funding	Inclusion/Exclusion Criteria	Baseline Demographic Data	Hospitalization Characteristics Time of Post-hospital Follow-up
Xiong, 2021(9) China Prospective Funding: Not reported	Inclusion: Ages 20-80 years, diagnosed with COVID-19, cured and discharged Exclusion: Severe and complex underlying diseases, receiving invasive treatment, women who were pregnant or breastfeeding Controls: free of COVID-19, similar demographics, completely quarantined at home for >3 months with little physical work	N=538 (those who completed telephone follow-up from group of 891 discharged) Age (years, median): 52 Gender (% male): 46 Race/ethnicity: NR Comorbidities: CHD: 3% CKD: 2% COPD: 4% DM: 7% HTN: 15% Obesity: NR Smoking: NR	COVID-19 severity: 5% critical, 34% severe, 62% general ICU admission: NR Respiratory support: NR Length of hospital stay: NR Planned time post-hospital: NR Reported time post-hospital (days, median): 97

Abbreviations: AKI=acute kidney injury; CAD=coronary artery disease; CKD=chronic kidney disease; CMR=cardiovascular magnetic resonance; COPD=chronic obstructive pulmonary disease; COVID-19=SARS-CoV-2: 2019 novel coronavirus; CPAP=continuous positive airway pressure; CVD=cardiovascular disease; DM=diabetes mellitus; ECMO=extracorporeal membrane oxygenation; ESKD=end stage kidney disease; HFNC=high-flow nasal cannula; HTN=hypertension; ICD=International Classification of Disease; IQR=interquartile range; ICU=intensive care unit; MRI=magnetic resonance imaging; NIV=non-invasive ventilation; NR=not reported; RT-PCR: reverse transcriptase polymerase chain reaction; VTE=venous thromboembolism; WHO=World Health Organization

Supplemental Table 3. Included Studies and Outcomes Reported

Author, year Country Sample Size (COVID-19/ control) Description of Controls	ICU Admission (%) Assessment Time Post- Discharge	Pulmonary Outcomes	Cardio- vascular Outcomes	Neurologic and Cognitive Outcomes	Renal Outcomes	Endocrine Outcomes	Gastro- intestinal Outcomes	Hematologic Outcomes
Al-Aly, 2021(1) USA 13,654/13,997 Historical controls; hospitalized for seasonal Influenza and survived 30 days after admission; propensity scores based on pre-defined variables estimated to adjust for potential confounders	26% COVID-19: 150 days Controls: 157 days (median)	Shortness of breath HR (adjusted) 1.14 (95%CI 1.04, 1.26) Excess burden per 1000 hospitalized COVID-19 patients at 6 months 13.22 (95%CI 3.68, 21.94)	Acute coronary disease^a HR (adjusted) 1.29 (95%CI 1.11, 1.50) Excess burden per 1000 hospitalized COVID-19 patients at 6 months 9.36 (95%CI 4.16, 13.86) Heart Failure^a HR (adjusted) 1.19 (95%CI 1.03, 1.39) Excess burden per 1000 hospitalized COVID-19 patients at 6 months 6.31 (95% CI 1.02, 10.88)	Stroke^a HR (adjusted) 1.30 (95%CI 1.05, 1.60) Excess burden per 1000 COVID-19 persons at 6 months 4.79 (95%CI 1, 7.87) Neuro- cognitive Disorders^a Excess burden per 1000 COVID-19 persons at 6 months 16.16 (95%CI 10.40, 21.19) Memory problems^a HR (adjusted) 1.42 (95%CI 1.23, 1.63) Excess burden per 1000	AKI^a HR (adjusted) 1.24 (95%CI 1.10, 1.40) Excess burden per 1000 COVID-19 persons at 6 months 11.21 (95%CI 5.36, 16.43) CKD^a HR (adjusted) 1.35 (95%CI 1.10, 1.65) Excess burden per 1000 COVID-19 persons at 6 months 6.03 (95%CI 2.17, 9.20)	Diabetes^a HR (adjusted) 1.60 (95%CI 1.36, 1.87) Excess burden per 1000 hospitalized COVID-19 patients at 6 months 21.39 (95%CI 15.10, 26.77)	“Gastro- intestinal Disorders” (includes dysphagia) ^a Excess burden per 1000 COVID-19 persons 19.28 (95%CI 12.75, 25.13)	Thrombo- embolism^a HR (adjusted) 2.26 (95% CI 1.94, 2.64) 25.74, 33.24) Pulmonary Embolism^a Excess burden per 1000 COVID-19 persons at 6 months 18.31 (95%CI 15.83, 20.25) Coagulation Disorder^a Excess burden per 1000 COVID-19 persons at 6 months 14.31 (95%CI 10.08, 17.89)

136/bmjopen-2022-061245 on 24 August 2022. Downloaded from <http://bmjopen.bmj.com/> on April 19, 2024 by guest. Protected by copyright.

Author, year Country Sample Size (COVID-19/ control) Description of Controls	ICU Admission (%) Assessment Time Post- Discharge	Pulmonary Outcomes	Cardio- vascular Outcomes	Neurologic and Cognitive Outcomes	Renal Outcomes	Endocrine Outcomes	Gastro- intestinal Outcomes	Hematologic Outcomes
				COVID-19 persons at 6 months 16.59 (95%CI 10.59, 21.84)				
Ayoubkhani, 2021(2) United Kingdom 47,780/47,780 Concurrent controls, general population, not meeting inclusion criteria for COVID-19; ≥1 record in general practice database in past year (ie, active patients); matched (1:1) on demographic and comorbidity factors	10% COVID-19: 140 days Controls 153 days (mean)	Respiratory Disease, new onset events COVID-19: 21.5% Control: 0.8% P<.001	MACE, new onset events COVID-19: 2.6% Control: 0.5% P<.001	NR	CKD, new onset events COVID-19: 0.6% Control: 0.3%	Diabetes, new onset events COVID-19: 1.1% Control: 0.3% P<.001	Chronic Liver Disease, new onset COVID-19: 0.2% Control: 0.04% P<.001	NR
Chevinsky, 2021(3) USA 27,284/27,284	40% COVID-19/ Controls	Respiratory failure; insufficiency; arrest	NR	Neuro- cognitive disorders 90-120 days after discharge	Acute and unspecified kidney failure 90-120 days after discharge	NR	NR	Acute Pulmonary Embolism 90-120 days after discharge

13616/mjopen-2022-061245 on 24 August 2022. Downloaded from <http://bmjopen.bmj.com/> on April 19, 2024 by guest. Protected by copyright.

Author, year Country Sample Size (COVID-19/ control) Description of Controls	ICU Admission (%) Assessment Time Post- Discharge	Pulmonary Outcomes	Cardio- vascular Outcomes	Neurologic and Cognitive Outcomes	Renal Outcomes	Endocrine Outcomes	Gastro- intestinal Outcomes	Hematologic Outcomes
Concurrent controls, hospitalized, did not meet inclusion for COVID-19; no diagnosis of COVID-19 during 4 months after index encounter; matched (1:1) on demographic, comorbidity, and socioeconomic factors	30-120 days (planned)	90-120 days after discharge OR (adjusted) 0.73 (95%CI 0.47, 1.10) Pneumonia (except that caused by tuberculosis) 90-120 days after discharge OR (adjusted) 1.00 (95%CI 0.58, 1.90)		OR (adjusted) 1.10 (95%CI 0.72, 1.70)	OR (adjusted) 0.56 (95%CI 0.39, 0.80)			OR (adjusted) 1.2 (95%CI 0.70, 2.10) Coagulation and Hemorrhagic Disorders 90-120 days after discharge OR (adjusted) 0.66 (95%CI 0.45, 0.97)
Daugherty, 2021(4) USA 18,118/18,118 Concurrent controls; no clinical diagnosis related to COVID-19, no positive test for SARS-CoV-2,	13% COVID-19/ Controls=120 days (mean)	New Clinical Diagnoses: Respiratory failure (acute respiratory failure, chronic respiratory failure, interstitial lung disease) COVID-19: 2.6% Control: 0.2%	New Diagnoses Coronary disease overall (MI, acute coronary syndrome, cardiogenic shock) COVID-19: 1.1% Control: 0.2% P<.001	Stroke (ischemic and hemorrhagic) COVID-19: 1.1% Control: 0.3% P<.001 New Clinical Diagnoses Amnesia/ memory difficulty	Kidney injury (acute and chronic) COVID-19: 3.0% Control: 0.8% Acute kidney injury COVID-19: 2.9% Control: 0.5% CKD	New Clinical Diagnoses Diabetes (Type 2) COVID-19: 3.0% Control: 0.8% P<.001	Liver Test Abnormality COVID-19: 3.3% Control: 1.4% P<.001	DVT COVID-19: 2.3% Control: 0.30% PE COVID-19: 1.3% Control: 0.1% P<.001 for all outcomes Hyper-coagulability COVID-19: 3.2% Control: 0.4%

Author, year Country Sample Size (COVID-19/ control) Description of Controls	ICU Admission (%) Assessment Time Post- Discharge	Pulmonary Outcomes	Cardio- vascular Outcomes	Neurologic and Cognitive Outcomes	Renal Outcomes	Endocrine Outcomes	Gastro- intestinal Outcomes	Hematologic Outcomes
no hospital admission for COVID-19, continuous health plan enrollment in past year, matched (1:1) on demographic, comorbidity, and provider visit factors		Risk difference 2.4% (95%CI 1.35, 3.20) Acute respiratory failure COVID-19: 2.6% Control: 0.18% Risk difference 2.4% (95%CI 1.67, 3.43) Chronic respiratory failure COVID-19: 1.5% Control: 0.1% Risk difference 1.5% (95%CI 0.97, 1.75) Interstitial lung disease COVID-19: 1.6% Control: 0.1%	Congestive Heart Failure COVID-19: 1.5% Control: 0.2% P<.001 Myocarditis COVID-19: 0.09% Control: 0.01% P=1.0	COVID-19: 2.9% Control: 0.4% P<.001 Dementia COVID-19: 0.2% Control: 0.03% P<.001 Alzheimer COVID-19: 0.04% Control: 0.0% P<.001	COVID-19: 2.1% Control: 0.7% P<.001 for both outcomes			P<.001

Author, year Country Sample Size (COVID-19/ control) Description of Controls	ICU Admission (%) Assessment Time Post- Discharge	Pulmonary Outcomes	Cardio- vascular Outcomes	Neurologic and Cognitive Outcomes	Renal Outcomes	Endocrine Outcomes	Gastro- intestinal Outcomes	Hematologic Outcomes
		Risk difference 1.5% (95%CI 1.14, 1.98) P<.001 for all outcomes						
Nugent, 2021(5) USA 182/1430 Concurrent controls; hospitalized, with AKI, negative test for COVID-19; analysis adjusted for demographic, comorbidity, and kidney function factors	37% COVID- 19=93 days Controls=61 days	NR	NR	NR	Kidney Recovery after Discharge (rate per 100 patient- days) COVID-19 Group (n=32) 0.95 (0.62, 1.46) Non-COVID Group (n=287) 1.74 (1.51, 2.00) HR (adj): 0.57 (0.35, 0.92); P=.02	NR	NR	NR
Puntmann, 2020(6) Germany 100 ^b /50 healthy controls/57 risk- factor matched controls	NR COVID-19/ Controls=NR (median time from diagnosis to	NR	CMR LGE Myocardial COVID-19: 32% Control: 0% Risk Factor- matched Control: 17%	NR	NR	NR	NR	NR

1361bmjopen-2022-061245 on 24 August 2022. Downloaded from <http://bmjopen.bmj.com/> on April 19, 2024 by guest. Protected by copyright.

Author, year Country Sample Size (COVID-19/ control) Description of Controls	ICU Admission (%) Assessment Time Post- Discharge	Pulmonary Outcomes	Cardio- vascular Outcomes	Neurologic and Cognitive Outcomes	Renal Outcomes	Endocrine Outcomes	Gastro- intestinal Outcomes	Hematologic Outcomes
<p>only 33% of COVID-19 group was hospitalized</p> <p>Healthy controls: normotensive, taking no cardiac medications, normal cardiac volume and function</p> <p>Risk-factor matched: pre-COVID patients, matched on demographic and comorbidity factors including known coronary artery disease</p>	<p>CMR was 71 days)</p>		<p>P<.05</p> <p>Pericardial COVID-19: 22% Control: 0% Risk Factor- matched Controls: 14%</p> <p>Pericardial Effusion >10 mm COVID-19: 20% Control: 0% Risk Factor- matched Control: 7% P<.05</p> <p>Detectable hsTNT ≥3 pg/mL COVID-19: 71% Control: 22% Risk Factor- matched Control: 54% P<.05</p> <p>Significantly elevated hsTNT ≥13.9 pg/mL</p>					

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Author, year Country Sample Size (COVID-19/ control) Description of Controls	ICU Admission (%) Assessment Time Post- Discharge	Pulmonary Outcomes	Cardio- vascular Outcomes	Neurologic and Cognitive Outcomes	Renal Outcomes	Endocrine Outcomes	Gastro- intestinal Outcomes	Hematologic Outcomes
			COVID-19: 5% Control: 0% Risk Factor- matched Control: 0% P<.05					
Raman, 2021(7) United Kingdom 58/30 Concurrent controls; community dwelling, negative for SARS-CoV-2 and asymptomatic, group matched for demographic and comorbidity factors	36% COVID-19 36 days (median) Controls not applicable	FVC <80% Predicted COVID-19: 13% Control: 0% P=.09 FEV₁<80% Predicted COVID-19: 10.7% Control: 0.4% P=.42 Dyspnea – mMRC ≥2 (significant breathlessness) COVID-19: 64.3% Control: 10.3% P<.0001 Lung Parenchymal Abnormalities COVID-19: 60.4% Control: 10.7%	Left Ventricular Function Normal and comparable between groups (data NR) LGE Myocarditis COVID-19: 12% Controls: 7% P=.47 Pericardial Effusion >10 mm COVID-19: 2% Controls: 0% P=1.0 Abnormal Troponin T COVID-19 0% Controls 0%	MoCA <26 (Abnormal) COVID-19: 28% Control: 17% P=.30 (calculated)	Residual Renal Impairment, new onset COVID-19: 3%	NR	NR	NR

13616/mjopen-2022-061245 on 24 August 2022. Downloaded from <http://bmjopen.bmj.com/> on April 19, 2024 by guest. Protected by copyright.

Author, year Country Sample Size (COVID-19/ control) Description of Controls	ICU Admission (%) Assessment Time Post- Discharge	Pulmonary Outcomes	Cardio- vascular Outcomes	Neurologic and Cognitive Outcomes	Renal Outcomes	Endocrine Outcomes	Gastro- intestinal Outcomes	Hematologic Outcomes
		P<.0001 VO₂ Peak <80% of Predicted Maximum COVID-19: 54.9% Control: 7.4% P<.0001						
Roberts, 2020(8) United Kingdom 1,877/18,159 Historical controls; discharged from hospital following medical admission (pre- COVID)	11% critical care COVID-19/ Controls=8 days (median)	NR	NR	NR	NR	NR	NR	VTE COVID-19: 0.5% 2 DVT, 7 PE Control (Medical Admissions in 2019): 0.3% 8 proximal, 10 distal, 5 line- associated upper-limb DVT, 33 PE OR 1.60 (95%CI 0.77, 3.10) P=.2
Xiong, 2021(9) China 538/184 Concurrent controls; non hospitalized,	NR COVID-19/ Controls=97 days (median)	NR	Newly Diagnosed Hypertension COVID-19: 1% Control: 0%	NR	NR	NR	NR	NR

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Author, year Country Sample Size (COVID-19/ control) Description of Controls	ICU Admission (%) Assessment Time Post- Discharge	Pulmonary Outcomes	Cardio- vascular Outcomes	Neurologic and Cognitive Outcomes	Renal Outcomes	Endocrine Outcomes	Gastro- intestinal Outcomes	Hematologic Outcomes
non-COVID with similar demographics								

^aIncludes participants without history of the outcome in the past one year

Abbreviations: AKI=acute kidney injury; CI=confidence interval; CKD=chronic kidney disease; CMR=cardiovascular magnetic resonance; COVID-19=SARS-CoV-2: 2019 novel coronavirus; DVT=deep venous thrombosis; FEV1 =forced expiratory volume in 1 sec; FVC=forced vital capacity; HR=hazard ratio; hsTNT=high-sensitivity Troponin T; LGE=late gadolinium enhancement; LVEF=left ventricular ejection fraction; mMRC=modified Medical Research Council; MoCA=Montreal Cognitive Assessment; MRI=magnetic resonance imaging; NR=not reported; OR=odds ratio; PE=pulmonary embolism; VTE=venous thromboembolism

136/bmjopen-2022-061245 on 24 August 2022 Downloaded from <http://bmjopen.bmj.com/> on April 18, 2024 by guest. Protected by copyright.

136/bmjopen-2022-026115 Protected by copyright.

Supplemental Table 4. Quality Ratings for Studies with Control Groups (shaded columns are database studies)

Criteria*	Al-Aly 2021(1)	Ayoubkhani 2021(2)	Chevinsky 2021(3)	Daugherty 2021(4)	Nugent 2021(5)	Puntmann 2020(6)	Raman 2021(7)	Roberts 2020(8)	Xiong 2021(9)
Were groups similar/recruited from same population?	No	No	Yes	No	Yes	Unclear	No	No	No
Was exposure measured similarly?	N/A	N/A	Yes	Yes	Yes	N/A	Yes	N/A	Unclear
Was exposure measured in valid and reliable way?	Yes	Yes	Unclear	Unclear	Yes	Yes	Yes	Unclear	Unclear
Were confounding factors identified?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Unclear	Unclear
Were strategies to deal with confounding factors stated?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	No
Were participants free of outcome at moment of exposure?	Yes	Yes	Yes	Yes	Yes	Unclear	Unclear	Unclear	Yes
Were outcomes measured in a valid and reliable way?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Unclear

Criteria*	Al-Aly 2021(1)	Ayoubkhani 2021(2)	Chevinsky 2021(3)	Daugherty 2021(4)	Nugent 2021(5)	Puntmann 2020(6)	Rangan 2021(7)	Roberts 2020(8)	Xiong 2021(9)
Was follow-up time reported and sufficient† for outcomes to occur?	Yes	Yes	Yes	Yes	Yes	Unclear	No	Yes	Yes
Was follow-up complete? If not, were reasons for loss described and explored?	Yes	Yes	Unclear	Yes	No/Yes – described	Yes	Yes	No/No	No/Yes - described
Were strategies to address incomplete follow-up utilized?	N/A	N/A	Unclear	N/A	Yes	N/A	No	No	No
Was appropriate statistical analysis used?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

N/A=not applicable

*JBI Critical Appraisal Checklist for Cohort Studies. Source: Moola S, Munn Z, Tufanaru C, et al. Chapter 7: Systematic reviews of etiology and risk. In Aromataris E, Munn Z (Eds) JBI Manual for Evidence Synthesis. JBI, 2020. Available from <https://synthesismanual.bji.global>. Accessed October 8, 2021.

†For this manuscript, ≥90 days was considered sufficient

136/bmjopen-2022-025125 on 24 August 2022. Downloaded from <http://bmjopen.bmj.com/> on April 18, 2024 by guest. Protected by copyright.

Supplemental Table References

1. Al-Aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19. *Nature*. 2021;594(7862):259-64.
2. Ayoubkhani D, Khunti K, Nafilyan V, Maddox T, Humberstone B, Diamond I, et al. Post-covid syndrome in individuals admitted to hospital with covid-19: retrospective cohort study. *BMJ*. 2021;372:n693.
3. Chevinsky JR, Tao G, Lavery AM, Kukielka EA, Click ES, Malec D, et al. Late conditions diagnosed 1-4 months following an initial COVID-19 encounter: a matched cohort study using inpatient and outpatient administrative data - United States, March 1-June 30, 2020. *Clin Infect Dis*. 2021;73:S5-S16.
4. Daugherty SE, Guo Y, Heath K, Dasmariñas MC, Jubilo KG, Samranvedhya J, et al. Risk of clinical sequelae after the acute phase of SARS-CoV-2 infection: retrospective cohort study. *BMJ*. 2021;373(n1098).
5. Nugent J, Akilil A, Yamamoto Y, Simonov M, Li F, Biswas A, et al. Assessment of acute kidney injury and longitudinal kidney function after hospital discharge among patients with and without COVID-19. *JAMA Netw Open*. 2021;4(3):e211095.
6. Puntmann VO, Carerj ML, Wieters I, Fahim M, Arendt C, Hoffman J, et al. Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19). *JAMA Cardiol*. 2020;5(11):1265-73.
7. Raman B, Cassar MP, Tunnicliffe EM, Filippini N, Griffanti L, Alfaro-Almagro F, et al. Medium-term effects of SARS-CoV-2 infection on multiple vital organs, exercise capacity, cognition, quality of life and mental health, posthospital discharge. *EClinicalMedicine*. 2021;31:100683.
8. Roberts LN, Whyte MB, Georgiou L, Giron G, Czuprynska J, Rea C, et al. Postdischarge venous thromboembolism following hospital admission with COVID-19. *Blood*. 2020;136(11):1347-50.
9. Xiong Q, Xu M, Li J, Liu Y, Zhang J, Xu Y, et al. Clinical sequelae of COVID-19 survivors in Wuhan, China: a single-centre longitudinal study. *Clin Microbiol Infect*. 2021;27(1):89-95.

PRISMA Checklist

Section/topic	#	Checklist item	Reported on page #
TITLE			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	2-3
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known.	4
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	4
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	3
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	5/Table 2
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	5
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	5/Suppl Table 1
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	5
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	6

Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	6
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	7
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	N/A
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I^2) for each meta-analysis.	7
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	N/A
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	N/A
RESULTS			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	7/Figure
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	708/Suppl Table 2
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	7-8/Suppl Table 4
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	9-15/Suppl Table 3
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	N/A
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	N/A
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	N/A
DISCUSSION			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	16-17

Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review level (e.g., incomplete retrieval of identified research, reporting bias).	16-17
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	17
FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	7, 18

Source: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097

BMJ Open

COVID-19 Post-acute Care Major Organ Damage: A Systematic Review

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2022-061245.R1
Article Type:	Original research
Date Submitted by the Author:	09-May-2022
Complete List of Authors:	Greer, Nancy; Minneapolis VA Health Care System Bart, Bradley; University of Minnesota, Department of Medicine; Minneapolis VA Health Care System Billington, Charles ; University of Minnesota, Department of Medicine; Minneapolis VA Health Care System Diem, Susan; University of Minnesota, Department of Medicine; Minneapolis VA Health Care System Ensrud, Kristine; University on Minnesota, Department of Medicine; Minneapolis VA Health Care System Kaka, Anjum; University of Minnesota, Department of Medicine; Minneapolis VA Health Care System Klein, Mark; University of Minnesota, Department of Medicine; Minneapolis VA Health Care System Melzer, Anne; Minneapolis Veterans Affairs Health Care System, Pulmonary, Allergy, Critical Care, and Sleep Medicine; University of Minnesota, Department of Medicine Reule, Scott; University of Minnesota, Department of Medicine; Minneapolis VA Health Care System Shaukat, Aasma; Univeristy of Minnesota, Department of Medicine; Minneapolis VA Health Care System, Sheets, Kerry; Minneapolis VA Health Care System; Hennepin Healthcare Starks, Jamie; University of Minnesota, Department of Medicine; Minneapolis VA Health Care System Vardeny, Orly; University of Minnesota, Department of Medicine; Minneapolis VA Health Care System McKenzie, Lauren; Minneapolis VA Health Care System Stroebe, Benjamin; Minneapolis VA Health Care System Macdonald, Roderick; Minneapolis VA Health Care System Sowerby, Katie; Minneapolis VA Health Care System Duan-Porter, Wei; Minneapolis VA Health Care System; University of Minnesota, Department of Medicine Wilt, Timothy; Minneapolis VA Health Care System, Center for Care Delivery and Outcomes Research; University of Minnesota, Department of Medicine
Primary Subject Heading:	Infectious diseases
Secondary Subject Heading:	Global health
Keywords:	COVID-19, STATISTICS & RESEARCH METHODS, INFECTIOUS DISEASES

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

COVID-19 Post-acute Care Major Organ Damage: A Systematic Review

Nancy Greer, PhD¹; Bradley Bart, MD^{2,3}; Charles J. Billington, MD^{2,4}; Susan J. Diem, MD, MPH^{1,2,5,6}; Kristine E. Ensrud, MD, MPH^{1,2,5,6}; Anjum Kaka, MD^{2,7}; Mark Klein, MD^{2,8}; Anne C. Melzer, MD, MS^{2,9}; Scott Reule, MD^{2,10}; Aasma Shaukat, MD, MPH^{1,2,11}; Kerry Sheets, MD^{1,2,12}; Jamie Starks, MD^{2,13}; Orly Vardeny, PharmD, MS^{1,2,14}; Lauren McKenzie, MPH¹; Benjamin Stroebel, MPH¹; Roderick MacDonald, MS¹; Katie Sowerby, BA¹; Wei Duan-Porter, MD, PhD^{1,2,5}; Timothy J. Wilt, MD, MPH^{1,2,5,15}

1. Center for Care Delivery and Outcomes Research, Minneapolis VA Health Care System, Minneapolis, MN
2. Department of Medicine, University of Minnesota, Minneapolis, MN
3. Division of Cardiology, Minneapolis VA Health Care System, Minneapolis, MN
4. Section of Endocrinology and Metabolism, Department of Medicine, Minneapolis VA Health Care System, Minneapolis, MN
5. General Internal Medicine, Minneapolis VA Health Care System, Minneapolis, MN
6. Division of Epidemiology and Community Health, University of Minnesota School of Public Health, Minneapolis, MN
7. Section of Infectious Diseases, Minneapolis VA Health Care System, Minneapolis, MN
8. Hematology/Oncology Section, Minneapolis VA Health Care System, Minneapolis, MN
9. Division of Pulmonary, Allergy, Critical Care, and Sleep Medicine, Minneapolis VA Health Care System, Minneapolis, MN
10. Division of Nephrology, Minneapolis VA Health Care System, Minneapolis, MN
11. Division of Gastroenterology, Minneapolis VA Health Care System, Minneapolis, MN
12. Division of Geriatrics, Hennepin Healthcare, Minneapolis, MN
13. Geriatric Research, Education, and Clinical Center, Minneapolis VA Health Care System, Minneapolis, MN
14. Department of Pharmacy, Minneapolis VA Health Care System, Minneapolis, MN
15. Division of Health Policy and Management, University of Minnesota School of Public Health, Minneapolis, MN

Corresponding Author

Nancy Greer, PhD

Minneapolis VA Health Care System

1 Veterans Drive

Minneapolis, MN 55417

Nancy.Greer@va.gov

612-467-4232

Abstract Word Count: 298

Manuscript Word Count: 3979

References: 30

Tables: 1

Figures: 1

Supplemental Tables: 4

ABSTRACT

Background: Major organ complications have been reported in patients hospitalized for coronavirus disease-2019 (COVID-19); most studies lacked controls.

Objective: Examine major organ damage post-discharge among adults hospitalized for COVID-19 vs non-COVID-19 controls.

Data sources: MEDLINE, Embase, and Cochrane Library from January 1, 2020 to May 19, 2021.

Study eligibility criteria: English language studies of adults discharged from hospital for COVID-19; reporting major organ damage. Single review of abstracts; independent dual review of full text.

Study appraisal and synthesis methods: Study quality was assessed using the Joanna Briggs Institute Appraisal Checklist for Cohort Studies. Outcome data were not pooled due to heterogeneity in populations, study designs, and outcome assessment methods; findings are narratively synthesized.

Results: Of 124 studies in a full evidence report, 9 included non-COVID controls and are described here. Four of the 9 (3 US, one UK) used large administrative databases. Four of the remaining 5 studies enrolled < 600 COVID-19 patients. Mean or median age ranged from 49-70 years with 46-94% male and 48-78% White race; 10-40% had been in intensive care units. Follow-up ranged from 4-22 weeks post-discharge. Four used hospitalized controls, 3 non-hospitalized controls, and 2 were unclear. Studies used various definitions of, and methods to assess, major organ damage outcomes. While the magnitude of effect differed across studies, incident cardiac, pulmonary, liver, acute and chronic kidney, stroke, diabetes, and coagulation disorders were consistently greater in adults hospitalized for COVID-19 compared with non-COVID-19 controls.

Limitations: Applicability to subgroups (age, gender, COVID severity, treatment, vaccination status) and non-hospitalized patients is unknown.

Conclusions and implications of key findings: Post-acute COVID-19 major organ damage is common and likely higher than controls. However, there is substantial uncertainty. More consistent reporting of

1
2
3 clinical outcomes and pre-COVID health status along with careful selection of control groups are needed
4
5 to address evidence gaps.
6
7
8

9 PROSPERO registration number CRD42020204788.
10
11
12
13
14
15

16 **STRENGTHS AND LIMITATIONS OF THIS STUDY**

- 17
18 • This systematic review examines clinically relevant major organ damage following hospitalization for
19 COVID-19 as reported in studies with a non-COVID-19 comparator group.
20
21
- 22 • We defined “post-acute COVID” as post-hospital discharge; applicability of findings to non-
23 hospitalized patients with acute COVID symptoms is unclear.
24
25
- 26 • Meta-analysis was inappropriate due to heterogeneity in populations, study designs, and methods of
27 outcome assessment.
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

INTRODUCTION

Coronavirus disease-2019 (COVID-19) is a viral illness that, as of May 2, 2022, was identified in over 511 million individuals (<https://www.who.int/emergencies/diseases/novel-coronavirus-2019>). Over 6.2 million deaths worldwide are attributed to COVID-19. In addition to the potential for severe acute pulmonary disease associated with coronavirus infections, there have been numerous reports of other major organ system manifestations and complications in patients hospitalized for COVID-19.¹⁻¹² These studies typically lacked controls without COVID-19 and it is not clear if post-discharge major organ system damage differs in patients hospitalized for COVID-19 from similar individuals without COVID-19.

Multi-organ damage¹³ and long-term clinical outcomes¹⁴ following infection with other coronaviruses such as severe acute respiratory syndrome (SARS) and Middle East Respiratory syndrome (MERS), have been previously reported. Because many COVID-19 patients are admitted to intensive care units, outcomes similar to those observed in post-intensive care syndrome or post-sepsis syndrome may be long-term consequences of COVID-19.¹⁵

We assessed post-acute care major organ damage prevalences in adults hospitalized for COVID-19 and determined if these differ compared with adults without COVID-19. Our review is limited to post-hospital major organ damage; a subset of post-acute sequelae of SARS-CoV-2 infection (PASC) (<https://www.nih.gov/about-nih/who-we-are/nih-director/statements/nih-launches-new-initiative-study>).

This manuscript is based on a living review conducted for the Department of Veterans Affairs (VA) Evidence Synthesis Program (ESP). The full review, now finalized, is available at:

<https://www.hsrd.research.va.gov/publications/esp/covid-organ-damage.cfm>

METHODS

This review was conducted in accordance with PRISMA standards. For the initial ESP living review (December 2020) and first update (June 2021), we included studies of adults hospitalized for *or with*

laboratory confirmed COVID-19. We prioritized post-acute major organ damage of greatest clinical relevance. We defined post-acute to include major organ damage reported at discharge or any time post-discharge. We included studies reporting relevant symptoms (such as dyspnea), laboratory data, or radiologic studies consistent with presence of a disease. We excluded studies reporting only general symptoms or studies reporting only mean/median values. For the September 2021 (final) update, we reported outcomes post-discharge and limited to studies with ≥ 50 COVID-19 patients.

We focus this manuscript on major organ damage from studies with at least 50 COVID-19 cases and any non-COVID-19 controls. In all studies, cases were hospitalized for COVID-19 (i.e., none were hospitalized for another condition with a subsequent positive test for SARS-CoV-2).

Data Sources and Searches

We searched MEDLINE, Embase, and the Cochrane Library from January 1, 2019 through May 19, 2021. The search strategy (Supplemental Table 1) was developed with input from expert medical librarians. We reviewed non-peer-reviewed public postings about post-COVID-19 complications for links to peer-reviewed data reports.

Study Selection

Consistent with rapid review methods, abstracts were reviewed by one investigator. A subset of 200 abstracts underwent dual independent review with substantial agreement between the two investigators. All articles identified as potentially eligible based on abstract review were independently reviewed by two investigators at the full-text level. Reasons for exclusion were noted. Conflicts were resolved by discussion. Inclusion and exclusion criteria are reported in Table 1.

Table 1. Study Eligibility Criteria

Study Characteristic	Include	Exclude
Population	Adults (age 18 and older); at least 50 case patients for manuscript	Children or adolescents, age <18; MERS; SARS
Intervention	Discharge from hospitalization after admission with or for proven COVID-19 ^a	Data only collected from patients during ongoing hospital acute-care admission with or for proven COVID-19
Comparator	Discharge from hospitalization for individuals without COVID-19 (ideally another respiratory condition); a comparator was not required for the living review but only studies with a control group are included in the manuscript	Not applicable
Outcomes	Prevalence and severity of major organ damage (respiratory, renal, cardiovascular, hematologic, neurologic and cognitive, endocrine, gastrointestinal, and hematologic); healthcare or service use needs related to major organ damage ^b	No outcomes of interest
Timing	Short-term (<3 months) and long-term (≥3 months) post-discharge	Not applicable
Setting	Any post-discharge setting (e.g., home, rehabilitation or long-term care facility); may include re-hospitalization	Not applicable
Study Designs	Cohort, case series, other observational; may prioritize articles using a best-evidence approach	Case report, narrative review, descriptive/opinion article with no data

^aIn the original and first update of the living review, we reported outcomes at the time of discharge. For the September 2021 update and this manuscript, patients must be discharged with post-discharge outcome data available.

^bIn the original version of the living review, we included studies reporting “re-positive” RT-PCR test results following discharge. For the June 2021 update and later versions, we excluded studies only reporting “re-positive” test results and removed those studies from the original set of included studies. As more information about the natural history of SARS-CoV-2 has become available, it has been recognized that patients may be PCR positive for prolonged periods after an initial COVID illness, and an isolated PCR positivity in such patients (especially for the first 90 days after diagnosis) does not by itself reflect a new infection. Healthcare or service use needs outcomes are not reported in the manuscript.

Data Extraction and Quality Assessment

Study characteristics (location, design, funding), inclusion and exclusion criteria, baseline demographic data (age, sex, race, comorbidities), hospitalization characteristics (COVID-19 severity, ICU admission, mechanical ventilation, length of hospital stay), length of time post-hospital, and outcomes were extracted by one investigator and verified by a second. Discrepancies were resolved by discussion.

We assessed study quality using the Joanna Briggs Institute Appraisal Checklist for Cohort Studies¹⁶ taking into account similarity between groups, assessment of the exposure and outcomes, adjustment for confounding factors, and completeness of follow-up.

Data Synthesis and Analysis

Due to heterogeneity in populations, study designs, and methods of outcome assessment, we were unable to pool outcomes data. We narratively synthesized the evidence.

Patient and Public Involvement: Neither patients nor the public were involved in this research.

Role of the Funding Source

This review is based on a living rapid review (final version completed) conducted for the VA Evidence Synthesis Program. and funded by the Veterans Health Administration Office of Research and Development, Health Services Research and Development Service. The funding source assigned the topic but was not involved in the study design, data collection, analysis, manuscript preparation, or submission.

RESULTS

Overview of Studies

Our literature search and study selection process are depicted in the Figure. From the 124 eligible references, 9 included controls.¹⁷⁻²⁵ Study inclusion and exclusion criteria, patient demographics, COVID-19, and hospitalization characteristics are reported in Supplemental Table 2.

In 7 of the 9 studies, controls were required to have either no positive COVID-19 test, diagnosis, or hospital admission for COVID-19,^{19-21,23} been quarantined at home for at least 3 months prior to study enrollment,²⁵ or been a patient in 2019 prior to COVID-19.^{17,24} Four studies included hospitalized controls,^{17,19,21,24} 3 included non-hospitalized controls,^{18,23,25} and 2 were unclear.^{20,22} Six studies created matched COVID-19 and control groups, matching on age, sex, race/ethnicity, geographic location, prior patient encounters, and comorbidities (Supplemental Table 2).^{17-20,22,23} One study adjusted for demographic and comorbidity factors²¹ and one recruited volunteers with “similar demographic characteristics”.²⁵

1
2
3 A total of 109,591 COVID-19 patients and 127,089 controls were enrolled. Four studies used
4 administrative databases (3 from the US and 1 from the UK) with sample sizes ranging from 13,654 to
5 47,780 COVID-19 patients.¹⁷⁻²⁰ The other 5 studies (2 from the UK, and 1 each from the US, Germany,
6 and China) enrolled from 58 to 1,877 COVID-19 patients.²¹⁻²⁵ Five studies reported outcomes
7 (Supplemental Table 3) for multiple organ systems^{17-20,23} while 4 focused on a single system –
8 cardiovascular,^{22,25} renal,²¹ or hematological.²⁴
9
10
11
12
13
14
15

16 In 5 studies reporting age, mean or median age ranged from 49-70 years.^{17,22,23,25} The percentage of males,
17 reported in 6 studies, ranged from 46-94%.^{17-19,22-25} There were no statistically significant differences
18 between COVID-19 and control groups for age or sex in any study.
19
20
21
22
23

24 Race was reported in 5 studies. In a study of US Veterans, 58% of the COVID-19 group and 73% of the
25 seasonal influenza control group were White.¹⁷ In a UK study, 78% of the COVID-19 group and 97% of
26 community-based controls were White.²³ In a US study, 41% of the COVID-19 group and 75% of the
27 non-COVID-19 group were White.²¹ In two other studies reporting race, the COVID-19 and control
28 groups were similar.^{18,19}
29
30
31
32
33
34

35 None of the large database studies reported on COVID-19 severity. Among the other 5 studies, one
36 identified the hospitalized subgroup as having severe COVID-19.²² One study included only patients with
37 moderate to severe COVID-19²³ while in another, 39% were identified as severe or critical.²⁵ The
38 percentage of COVID-19 patients receiving invasive mechanical ventilation or extracorporeal membrane
39 oxygenation ranged from 6-29% (k=3).
40
41
42
43
44
45
46

47 Study quality assessments are reported in Supplemental Table 4. Only 2 studies recruited COVID-19 and
48 control patients from the same populations (i.e., concurrent, hospitalized patients).^{19,21} All but 2^{24,25} dealt
49 with potential confounders using matching or adjusted analyses. In most studies, the outcome of interest
50 was a new, post-COVID-19 event. In the database studies, events were identified with International
51 Classification of Diseases version 10 (ICD-10) codes while the smaller studies used laboratory testing,
52
53
54
55
56
57
58
59
60

1
2
3 imaging, or self-report. Follow-up ranged from 48-150 days. Most studies provided reasons for
4 incomplete follow-up via a patient flow diagram.

7 **Respiratory Disease**

8
9 Five studies provided pulmonary outcomes (Supplemental Table 3).^{17-20,23} Two reported on baseline
10 COPD or current smoking status with 5-14% of COVID-19 patients (0%-12% of controls) having COPD
11 and 8-35% of COVID-19 patients (8-23% of controls) being current smokers.

12
13
14
15
16
17 Three large database studies reported incident respiratory disease. A UK study reported that patients with
18 COVID-19, at 146 days post-discharge, had significantly higher new onset respiratory disease (ICD-10
19 codes J00-99) (22% [6,085/28,335]) compared to general population, non-hospitalized controls (0.8%
20 [240/28,335]; $P < .001$).¹⁸ A US study, with over 54,000 records, reported a significantly increased odds
21 for new onset pneumonia at 1-30 days post-discharge in the COVID-19 group versus hospitalized non-
22 COVID controls (OR 5.5 [95%CI 4.1, 7.5]).¹⁹ The difference was no longer statistically significant at 31-
23 60, 61-90, and 91-120 days post-discharge. Similarly, patients with COVID-19 were more likely to have
24 “respiratory failure, insufficiency, or arrest” at 0-30 days post discharge as compared to non-COVID
25 controls (OR 3.3 [95%CI 2.6, 4.1]), but not at later follow-up. A US study, with over 36,000 records,
26 reported a higher incidence of the combined outcome of “overall respiratory failure at 4 months after
27 acute illness” in the COVID-19 group (2.6%) compared to non-COVID controls (0.2%) ($P < .001$).²⁰ A
28 higher incidence in the non-COVID-19 group was also noted for acute respiratory failure, chronic
29 respiratory failure, and interstitial lung disease.

30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45 Only one study reported pulmonary function tests and found no statistically significant difference among
46 COVID-19 cases (n=56) and non-hospitalized, non-COVID controls (n=30) in the percentage of
47 individuals having an abnormal (<80% predicted) FEV₁ (11% COVID-19, 0.4% control; $P = .42$) or FVC
48 (13% COVID-19, 0% control; $P = .09$) at 48 days post-discharge.²³

Measures of dyspnea were reported in 2 studies. Shortness of breath was greater in hospitalized US Veterans with COVID-19 (n=13,654) compared with historical controls hospitalized for seasonal influenza (n=13,997) (Hazard Ratio (HR) 1.14 [95%CI 1.04, 1.26]; excess burden per 1000 hospitalized at 6 months: 13.2 [95%CI 3.7, 21.9]).¹⁷ In another study “significant breathlessness” based on the mMRC dyspnea scale (<https://mrc.ukri.org/research/facilities-and-resources-for-researchers/mrc-scales/mrc-dyspnoea-scale-mrc-breathlessness-scale/>) was reported in 36/56 (64%) COVID-19 patients compared with 3/29 (10%) non-hospitalized, non-COVID cases at 48 days post-discharge.²³

Cardiovascular Outcomes

Five studies reported cardiovascular outcomes (Supplemental Table 3).^{17,18,20,22,25} Two reported presence of cardiovascular disease at baseline (3-13% of COVID-19 patients, 5-16% of controls) and 3 reported hypertension at baseline (15-52% of COVID-19 patients, 17-52% of controls).

Three large database studies reported diagnoses of cardiovascular disease following hospitalization for COVID-19. The study of over 27,000 Veterans reported greater incident acute coronary disease (HR 1.3 [95%CI 1.1, 1.5]) and heart failure (HR 1.2 [95%CI 1.03, 1.4]) for the COVID-19 group vs historical controls hospitalized with seasonal influenza during the 6 months following hospitalization.¹⁷

A second study from the US, including over 36,000 individuals in COVID-19 and concurrent non-COVID control groups, reported new cardiac diagnoses over 4 months follow-up.²⁰ Coronary disease (including myocardial infarction, acute coronary syndrome, and cardiogenic shock) was reported in 1.1% of the COVID-19 group and 0.2% of controls (P<.001). Congestive heart failure was reported in 1.5% of the COVID-19 group and 0.2% of controls (P<.001). Myocarditis incidence was rare and the difference between groups was not statistically significant (COVID-19: 0.09%, Control: 0.01%; P=1.0).

A study from the UK reported major adverse cardiovascular events (MACE) defined as heart failure, myocardial infarction, stroke, and arrhythmia, during a mean of 146 days post-discharge.¹⁸ New events

1
2
3 were reported in 2.6% (945/36,130) of the COVID-19 group and 0.5% (190/36,130) of the general
4
5 population control group ($P<.001$).
6
7

8 One smaller study used echocardiography to assess left ventricular ejection fraction at 48 days post-
9
10 discharge.²³ Left ventricular function was normal and comparable between the COVID-19 group and a
11
12 community dwelling non-COVID group.
13
14

15 Two studies used cardiovascular magnetic resonance imaging (CMR) to assess myocardial injury. In a
16
17 study from Germany, 100 patients (33 of whom had been hospitalized) were assessed at a median of 71
18
19 days following diagnosis.²² Late gadolinium enhancement (LGE), reflecting scarring, was observed in
20
21 32% (32/100) (myocardial) and 22% (22/100) (pericardial) of the COVID-19 group. Myocardial LGE
22
23 was significantly more prevalent ($P<.05$) in COVID-19 patients than in healthy controls (0%) or risk
24
25 factor-matched controls (17% (9/57)). Pericardial LGE was significantly more prevalent ($P<.05$) in
26
27 COVID-19 patients than in healthy controls (0%) but not risk factor-matched controls (14% (8/57)).
28
29
30

31 A second study assessed outcomes at a median of 48 days post-discharge. LGE (myocarditis pattern) was
32
33 observed in 12% (6/52) of the COVID-19 group (moderate to severe disease) and 7% (2/28) of
34
35 community-dwelling, non-COVID controls ($P=.47$).
36
37

38 The studies also reported on presence of pericardial effusion based on CMR. The study from Germany
39
40 reported pericardial effusion (>10 mm) in 20% (20/100) of COVID-19 patients, 0% of healthy controls,
41
42 and 7% (4/57) of risk factor-matched controls ($P<0.05$ for the COVID-19 group vs each control group) at
43
44 a median of 71 days following diagnosis.²² The other study reported pericardial effusion (>10 mm) in 2%
45
46 (1/52) of the COVID-19 group and 0% (0/28) of community dwelling, non-COVID controls at a median
47
48 of 48 days post-discharge.²³
49
50

51
52 The CMR study from Germany²² reported detectable high-sensitivity troponin T (hsTNT) (>3 pg/mL) in
53
54 71% (71/100) of the COVID-19 group, with significantly elevated hsTNT (>13.9 pg/mL) in 5% (5/100) at
55
56
57

1
2
3 a median of 71 days following diagnosis. The percentage of patients with detectable hsTNT was
4 significantly higher ($P<.05$) in the COVID-19 group than in healthy (22% [11/50] or risk factor-matched
5 controls (54% [31/57]). The second study, with a control group of non-COVID-19 community members
6 reported no cases of abnormal troponin T in either the COVID-19 or control groups at a median of 48
7 days post-discharge.²³

13 **Neurologic and Cognitive Outcomes:**

14 Neurologic and cognitive outcomes were reported by 4 studies (Supplemental Table 3).^{17,19,20,23}

15
16 The study of over 27,000 US Veterans reported an increased risk of stroke 6 months after hospitalization
17 for COVID-19 among individuals without a history of stroke in the past year, as compared to historical,
18 matched controls with seasonal influenza (HR 1.30; 95%CI 1.05, 1.60).¹⁷ Another US study reported the
19 prevalence of new onset stroke during the 4 months post-hospitalization.²⁰ Ischemic and hemorrhagic
20 stroke was reported in 1.1% of the COVID-19 group and 0.3% of matched non-COVID controls (risk
21 difference 0.8% [95%CI 0.4, 1.2], $P<.001$).

22
23 For incident neurocognitive disorders, US Veterans hospitalized for COVID-19 had an excess burden per
24 1000 COVID-19 persons at 6 months of 16.2 (95%CI 10.4, 21.2) compared to hospitalized seasonal
25 influenza cases.¹⁷ In another database study, neurocognitive disorders, defined using the Clinical
26 Classification Software Refined (CCSR) categories, were more likely in patients hospitalized with
27 COVID-19 vs non-COVID controls (OR 1.6 [95%CI 1.2, 2.1]) in the first 30 days after discharge but not
28 at 60, 90, or 120 days.¹⁹

29
30 In a US database study enrolling adults age 18-65 years, newly diagnosed dementia through 120 days
31 post-acute infection was greater in the COVID-19 group compared to non-COVID controls (0.2% vs
32 0.03%; risk difference 0.2% [95%CI 0.7, 0.3], $P<.001$).²⁰ In the same study, Alzheimer-type dementia
33 was noted in 0.04% of the COVID-19 group and 0% of controls ($P<.001$).

1
2
3 One study reported Montreal Cognitive Assessment (MoCA) scores of less than 26 (i.e., cognitive
4 impairment) in 28% of the COVID-19 group and 17% of community-based controls ($P=.30$) at a median
5 of 48 days post-discharge.²³
6
7

8 **Renal Outcomes**

9
10 Renal outcomes were reported by 6 studies (Supplemental Table 3).^{17-21,23} A history of chronic kidney
11 disease (CKD) at baseline, reported in 2 studies, was noted in 13% of patients in both the COVID-19 and
12 the control groups in one study¹⁸ and 33% of the COVID-19 group and 35% of controls in the other.²¹
13

14
15 CKD post COVID-19, identified by ICD-10 codes, was reported in 3 large database studies.^{17,18,20} In the
16 study of US Veterans, the HR for a new diagnosis of CKD during the 6 months after acute infection in the
17 COVID-19 group vs seasonal influenza controls was 1.4 (95%CI 1.1, 1.7).¹⁷ A second US study, with
18 data from over 36,000 individuals, reported new diagnoses of CKD (all stages) at 4 months after acute
19 illness in 2.1% of the COVID-19 group and 0.7% of non-COVID controls ($P<.001$).²⁰ The third study,
20 completed in the UK, included data from over 82,000 individuals and reported new onset CKD stages 3-5
21 in 0.6% of the COVID-19 group and 0.3% of general population controls at a mean of approximately 146
22 days post-discharge.¹⁸
23
24
25
26
27
28
29
30
31
32
33
34

35
36 A new diagnosis of acute kidney injury (AKI) following discharge was reported in 3 large database
37 studies.^{17,19,20} The study of US Veterans reported an adjusted HR for AKI during the 6 months following
38 COVID-19 infection for the COVID-19 group vs seasonal influenza controls (HR 1.2 [95%CI 1.1, 1.4]).¹⁷
39 A second US study reported ORs for “acute and unspecified kidney failure” vs hospitalized non-COVID-
40 19 controls.¹⁹ ORs decreased from 1.3 (95%CI 1.0, 1.6) at 30 days post-discharge to 0.6 (95%CI 0.4, 0.8)
41 at 120 days post-discharge. The third study, also from the US, reported a new diagnosis of AKI during the
42 4 months after acute infection in 2.9% of the COVID-19 group and 0.5% of non-COVID controls
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 In a study of patients with COVID-19 associated AKI, defined as >50% increase in creatinine over
4 baseline or 0.3 mg/dl increase over lowest level at 48 hours, and a control group with non-COVID
5 associated AKI, the COVID-19 group demonstrated lower rates of AKI recovery post hospital discharge
6
7 (HR_{adj} 0.57 [95% CI 0.35, 0.92]; P=.02).²¹
8
9

11 **Endocrine**

12
13 Three database studies, 2 from the US^{17,20} and 1 from the UK,¹⁸ reported the presence of diabetes
14 (Supplemental Table 3). Diabetes at baseline was reported in one study (24%).¹⁸ A US study, with data
15 from over 27,000 Veterans without a history of diabetes in the previous year, reported greater risk for
16 diabetes in the COVID-19 group than in a matched, seasonal influenza control group (HR 1.6 [95%CI
17 1.4, 1.9]).¹⁷ The excess burden per 1000 hospitalized COVID-19 patients was 21.4 (95%CI 15.1, 26.8) at
18 6 months following COVID-19 infection. The second US study included over 36,000 hospitalized
19 patients in COVID-19 and matched non-COVID-19 groups. Through 4 months after acute illness, a new
20 clinical diagnoses of Type 2 diabetes was reported in 3% of the COVID-19 group and 0.8% of controls
21 (risk difference 2.2% [95%CI 1.4, 3.2]).²⁰
22
23
24
25
26
27
28
29
30
31
32

33 The UK study, with data from over 72,000 individuals (COVID-19 and matched, general population
34 controls) reported new onset Type 1 diabetes, during a mean of approximately 146 days after discharge,
35 in 1.1% (400/36,100) of the COVID-19 group and 0.3% (125/36,100) of controls.¹⁸ Rates per 1000
36 person-years were 28.7 for the COVID-19 group and 8.2 for controls.
37
38
39
40
41

42 **Gastrointestinal Outcomes**

43
44 Three studies reported gastrointestinal outcomes (Supplemental Table 3).^{17,18,20} Two database studies
45 identified gastrointestinal disease using ICD-10 codes.^{17,18} The study of Veterans identified incidence of
46 gastrointestinal disorders (e.g., dysphagia) in over 27,000 individuals hospitalized for either COVID-19
47 or seasonal influenza.¹⁷ During 6 months follow-up, the excess burden per 1000 COVID-19 persons was
48 19.3 (95%CI 12.8, 25.1). The second study, from the UK (46,395 matched pairs), identified new onset
49 chronic liver disease over a mean follow-up of 140 days among individuals hospitalized with COVID-19
50
51
52
53
54
55
56
57
58
59
60

(0.2% [70/46,395]) compared to a non-hospitalized general population (0.04% [15/46,395]).¹⁸ The difference was statistically significant ($P<.001$). The third study, enrolling over 18,000 matched pairs, reported liver test abnormalities at 4 months after acute illness in 3.3% of the COVID-19 group and 1.4% of the control group ($P<.001$).²⁰

Hematologic Outcomes

Three studies reported venous thromboembolism (VTE) outcomes post-discharge (Supplemental Table 3).^{17,19,20} A US study, including data from over 54,000 individuals, reported ORs for acute pulmonary embolism (PE) vs non-COVID controls of 1.5 (95%CI 1.0, 2.1) at 30 days post-discharge and 1.4 (95%CI 0.9, 2.1) at 60 days. ORs at 90 and 120 days were also not statistically significant.¹⁹ Another US study, with data from over 36,000 individuals, reported PE in 1.3% of the COVID-19 group and 0.1% of the non-COVID controls through 120 days post-infection.²⁰ Deep venous thrombosis was reported in 2.3% of the COVID-19 group and 0.3% of controls. The study of over 27,000 US Veterans observed an excess burden for PE per 1000 COVID-19 persons (vs seasonal influenza controls) of 18.3 (95%CI 15.8, 20.3) and an HR for thromboembolism of 2.3 (95%CI 1.9, 2.6) through 150 days post-discharge.¹⁷

The same studies reported coagulation disorders (with varying definitions of “coagulation” between studies). The study of over 27,000 US Veterans reported an excess burden of coagulation (defined by ICD-10 codes, not specified) per 1000 COVID-19 persons of 14.3 (95%CI 10.1, 17.9) compared to seasonal influenza controls.¹⁷ Another US study reported a higher risk of hypercoagulability (ICD-10 codes D68 and I82) in the COVID-19 group (3.2%) than in non-COVID controls (0.4%) during the 4 months after acute illness.²⁰ The risk difference was 2.8% (95%CI 2.3, 3.6) ($P<.001$). The third study, also from the US, reported odds ratios (COVID-19 vs hospitalized non-COVID-19 controls) for the overall category of coagulation and hemorrhagic disorders.¹⁹ The ORs at 30, 60, 90, and 120 days were 1.3 (95%CI 1.0, 1.6), 1.3 (95%CI 0.95, 1.7), 0.65 (95%CI 0.5, 0.9), and 0.66 (95%CI 0.5, 0.97), respectively. It was noted that the top 5 coagulation and hemorrhagic disorders were “unspecified

1
2
3 thrombocytopenia, other primary thrombophilia, other secondary thrombocytopenia, unspecified
4
5 coagulation defect, and other thrombophilia”.

6 7 **CONCLUSIONS**

8 9 **Key Findings**

10
11 Our review of COVID-19 post-acute major organ damage found that incident respiratory disease may be
12
13 higher in post-hospitalization COVID-19 cases as compared to non-COVID controls. Prevalence ranged
14
15 from 2% to 22% in COVID-19 groups compared to less than 1% in controls. Dyspnea was much more
16
17 prevalent (64% vs 10%) and there was greater risk for dyspnea in COVID-19 groups than in controls.

18
19
20
21 Patients with COVID-19 were also at greater risk for incident cardiovascular disease outcomes (including
22
23 acute myocardial infraction, coronary disease, and heart failure) compared to controls. Prevalence of new
24
25 cardiovascular events ranged from approximately 1% to 3% in the COVID-19 groups and less than 1% in
26
27 controls. One large database study reported that a clinical diagnosis of myocarditis based on ICD-10
28
29 codes was rare and did not differ between those with COVID-19 and controls (0.09% vs 0.01%; $P=1.0$).
30
31 However, 2 small studies used MRI to assess prevalence of myocarditis based on LGE patterns. One
32
33 specifically excluded individuals with active cardiac symptoms and the other did not require symptoms to
34
35 proceed to MRI. LGE based “myocarditis” in these 2 studies was much higher compared to the database
36
37 report and was noted in 12% vs 7% ($P=0.47$) and 32 vs 17% ($p<0.05$) of COVID-19 patients and controls,
38
39 respectively.

40
41
42
43 Among other organ systems, the prevalence, or risk for, stroke, new onset chronic kidney disease, acute
44
45 kidney injury, new onset diabetes, incident gastrointestinal disorders, and new onset chronic liver disease
46
47 was higher in COVID-19 groups than in matched controls. The incidence of dementia post-COVID-19
48
49 was low but may exceed that of non-COVID cases. The prevalence of, or risk for, coagulation and
50
51 hemorrhagic disorders was higher in COVID-19 groups than in control groups though disorder definitions
52
53 were unclear and varied.
54
55
56
57

1
2
3 Limitations of the evidence exist. Although evidence includes 4 large database studies with controls, most
4 data, cited in the living review, are from small single center convenience sample studies with poorly
5 described populations or measures of major organ damage. Among the 9 studies with controls cited in this
6 manuscript, control groups varied. Three studies included historical controls and 6 included concurrent
7 controls. In 4 of the concurrent control studies, control group patients were not hospitalized. Reported
8 prevalence rates are likely highly dependent on pre-existent demographics and comorbidities of the study
9 population, COVID-19 disease severity, the measures used to assess and define major organ damage, and
10 the timing of assessment relative to hospital discharge. Follow-up times for the 9 studies with control
11 groups ranged from 30 to 150 days; only one study reported outcomes at multiple time points post-
12 COVID. Long-term major organ damage (i.e., ≥ 6 months) prevalence and duration of major organ
13 damage remain unknown. There are no data reporting on outcomes based on patient living situation prior
14 to COVID-19 infection (i.e., community dwelling versus nursing home or assisted care centers). No data
15 exist to ascertain if outcomes differ based on treatments received for COVID-19, COVID-19 vaccination
16 status, or infection with different COVID-19 variants, especially the delta variant. Disease diagnosis
17 relied on clinician coding rather than a standardized physiologic/laboratory value. There are also
18 limitations of our review methods. We defined “post-acute COVID” as post-hospital discharge. The
19 applicability of these findings to non-hospitalized patients with acute COVID symptoms is unclear.

20
21
22 We are aware of several systematic reviews reporting persistent symptoms following recovery from acute
23 COVID-19.²⁶⁻³⁰ Fatigue, dyspnea, chest pain, sleep disorders, cognitive impairment, and difficulty
24 concentrating are commonly reported symptoms. Our review complements these reviews by focusing on
25 1) patients requiring hospitalization for laboratory-confirmed COVID-19, 2) major organ damage from all
26 organ systems rather than symptoms, and 3) controlled studies.

27
28
29 In conclusion, post-acute COVID-19 major organ damage following hospitalization for COVID-19
30 infection is common and likely higher than non-COVID controls. However, there is substantial

1
2
3 uncertainty due to evidence limitations. More consistent reporting of clinically relevant outcomes and pre-
4
5 COVID health status as well as use of appropriately matched controls is needed to address evidence gaps.
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Contributors:

Conception/design: NG, BB, CJB, SJD, KEE, AK, MK, ACM, SR, AS, KS, JS, OV, WD-P, TJW

Acquisition, analysis, or interpretation of data: NG, BB, CJB, SJD, KEE, AK, MK, ACM, SR, AS, KS, JS, OV, LM, BS, RM, KS, WD-P, TJW

First draft of the manuscript: NG, TJW

Manuscript drafting, revision, approval: NG, BB, CJB, SJD, KEE, AK, MK, ACM, SR, AS, KS, JS, OV, LM, BS, RM, KS, WD-P, TJW

Overall guarantors: NG, TJW

Funding: This work was supported by the Department of Veterans Affairs, Veterans Health

Administration, Health Services Research and Development, Evidence Synthesis Program, Grant #09-009

Ethics Approval: This study does not involve human participants. This study does not involve animal subjects.

Competing Interests: None declared

Data Sharing: All data are available in Supplemental Tables 2 and 3.

REFERENCES

1. Gupta A, Madhavan MV, Sehgal K, et al. Extrapulmonary manifestations of COVID-19. *Nat Med*. 2020;26(7):1017-1032.
2. Mitrani RD, Dabas N, Goldberger JJ. COVID-19 cardiac injury: Implications for long-term surveillance and outcomes in survivors. *Heart Rhythm*. 2020;17(11):1984-1990.
3. Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. *Nat Med*. 2021;27(4):601-615.
4. Chen YT, Shao SC, Hsu CK, Wu IW, Hung MJ, Chen YC. Incidence of acute kidney injury in COVID-19 infection: a systematic review and metaanalysis. *Crit Care*. 2020;24(1):346.
5. Hirsch JS, Ng JH, Ross DW, et al. Acute kidney injury in patients hospitalized with COVID-19. *Kidney Int*. 2020;98(1):209-218.
6. Varatharaj A, Thomas N, Ellul MA, et al. Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study. *Lancet Psychiatry*. 2020;7(10):875-882.
7. Korolnik IJ, Tyler KL. COVID-19: A global threat to the nervous system. *Ann Neurol*. 2020;88(1):1-11.
8. Bikdeli B, Madhavan MV, Jimenez D, et al. COVID-19 and thrombotic or thromboembolic disease: Implications for prevention, antithrombotic therapy, and follow-up. *J Am Coll Cardiol*. 2020;75(23):2950-2973.
9. Bilaloglu S, Aphinyanaphongs Y, Jones S, Iturrate E, Hochman J, Berger JS. Thrombosis in hospitalized patients with COVID-19 in a New York City Health System. *JAMA*. 2020;324(8):799-801.
10. Connors J, Levy J. COVID-19 and its implications for thrombosis and anticoagulation. *Blood*. 2020;135(23):2033-2040.
11. Rubino F, Amierl SA, Zimmet P, et al. New-onset diabetes in Covid-19. *N Engl J Med*. 2020;383(8):789-790.
12. Hajifathalian K, Krisko T, Mehta A, et al. Gastrointestinal and hepatic manifestations of 2019 novel coronavirus disease in a large cohort of infected patients from New York: Clinical implications. *Gastroenterology*. 2020;159(3):1137-1140.
13. Renu K, Prasanna PL, Gopalkrishnan AV. Coronaviruses pathogenesis, comorbidities and multi-organ damage – A review. *Life Sci*. 2020;255:117839.
14. Ahmed H, Patel K, Greenwood D, et al. Long-term clinical outcomes in survivors of coronavirus outbreaks after hospitalisation or ICU admission: A systematic review and meta-analysis. *J Rehabil Med*. 2020;52(5):jrm00063.
15. Prescott HC, Girard TD. Recovery from severe COVID-19: Leveraging the lessons of survival from sepsis. *JAMA*. 2020;324(8):739-740.
16. Moola S, Munn Z, Tufanaru C, et al. Chapter 7: Systematic reviews of etiology and risk. In: Aromataris E, Munn Z, eds. *JBIM Manual for Evidence Synthesis*, 2020.
17. Al-Aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19. *Nature*. 2021;594(7862):259-264.
18. Ayoubkhani D, Khunti K, Nafilyan V, et al. Post-covid syndrome in individuals admitted to hospital with covid-19: retrospective cohort study. *BMJ*. 2021;372:n693.
19. Chevinsky JR, Tao G, Lavery AM, et al. Late conditions diagnosed 1-4 months following an initial COVID-19 encounter: a matched cohort study using inpatient and outpatient administrative data - United States, March 1-June 30, 2020. *Clin Infect Dis*. 2021;73:S5-S16.
20. Daugherty SE, Guo Y, Heath K, et al. Risk of clinical sequelae after the acute phase of SARS-CoV-2 infection: retrospective cohort study. *BMJ*. 2021;373:n1098.


21. Nugent J, Aklilu A, Yamamoto Y, et al. Assessment of acute kidney injury and longitudinal kidney function after hospital discharge among patients with and without COVID-19. *JAMA Netw Open*. 2021;4(3):e211095.
22. Puntmann VO, Carerj ML, Wieters I, et al. Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19). *JAMA Cardiol*. 2020;5(11):1265-1273.
23. Raman B, Cassar MP, Tunnicliffe EM, et al. Medium-term effects of SARS-CoV-2 infection on multiple vital organs, exercise capacity, cognition, quality of life and mental health, posthospital discharge. *EClinicalMedicine*. 2021;31:100683.
24. Roberts LN, Whyte MB, Georgiou L, et al. Postdischarge venous thromboembolism following hospital admission with COVID-19. *Blood*. 2020;136(11):1347-1350.
25. Xiong Q, Xu M, Li J, et al. Clinical sequelae of COVID-19 survivors in Wuhan, China: a single-centre longitudinal study. *Clin Microbiol Infect*. 2021;27(1):89-95.
26. Groff D, Sun A, Ssentongo AE, et al. Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection: a systematic review. *JAMA Netw Open*. 2021;4(10):e2128568.
27. Michelen M, Manoharan L, Elkheir N, et al. Characterising long COVID: a living systematic review. *BMJ Glob Health*. 2021;6(9):e005427.
28. Nasserie T, Hittle M, Goodman SN. Assessment of the frequency and variety of persistent symptoms among patients with COVID-19: A systematic review. *JAMA Netw Open*. 2021;4(5):e2111447.
29. van Kessel SAM, Olde Hartman TC, Lucassen PLBJ, van Jaarsveld CHM. Post-acute and long-COVID-19 symptoms in patients with mild diseases: a systematic review. *Fam Pract*. 2021:cmab076.
30. Cabrera Martimbianco AL, Pacheco RL, Bagattini AM, Riera R. Frequency, signs and symptoms, and criteria adopted for long COVID-19: A systematic review. *Int J Clin Pract*. 2021;75(10):e14357.

1
2
3 Figure Legend
4
5

6 Figure. Literature Flow Diagram
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Figure. Literature Flow Diagram



^aStudies may have reported more than 1 category of outcomes

Supplemental Table 1. MEDLINE/EMBASE Search Strategy

1 (coronavir* or corona virus* or betacoronavir* or covid19 or covid 19 or nCoV or CoV 2 or
 2 CoV2 or sarscov2 **SARS 2** or **SARS-CoV-2** or 2019nCoV or 2019 novel coronavirus* or 2019
 3 novel CoV or wuhan virus* or ((wuhan or hubei or huanan) and (severe acute respiratory or
 4 pneumonia*))).ti,ab,kw.
 5
 6 2 Coronavirus Infections/ or Coronavirus/ or betacoronavirus/
 7 3 1 or 2
 8 4 Pulmonary fibrosis.ti,ab,kw. or exp Pulmonary Fibrosis/
 9 5 exp Lung Diseases, Obstructive/
 10 6 4 or 5
 11 7 acute kidney injury.ti,ab,kw. or exp Acute Kidney Injury/
 12 8 exp Renal Insufficiency, Chronic/
 13 9 (end stage renal disease or ESRD or AKI or CKD).ti,ab,kw.
 14 10 7 or 8 or 9
 15 11 myocardial infarction.ti,ab,kw. or exp Myocardial Infarction/
 16 12 (heart attack or heart failure or MI).ti,ab,kw.
 17 13 myocarditis.ti,ab,kw. or exp Myocarditis/
 18 14 exp Arrhythmias, Cardiac/
 19 15 arrhythmia*.ti,ab,kw.
 20 16 11 or 12 or 14 or 14 or 15
 21 17 exp Venous Thrombosis/
 22 18 exp Pulmonary Embolism/ or exp Venous Thromboembolism/
 23 19 (deep ve* thrombosis or DVT or pulmonary embolism or PE).ti,ab,kw.
 24 20 anemia.ti,ab,kw. or exp Anemia/
 25 21 17 or 18 or 19 or 20
 26 22 stroke.ti,ab,kw. or exp Stroke/
 27 23 exp Cognitive Dysfunction/
 28 24 exp Confusion/
 29 25 exp Seizures/
 30 26 exp Headache/
 31 27 (stroke* or cerebrovascular accident* or cognitive impairment or cognitive dysfunction or
 32 delirium or confusion or seizure* or headache*).ti,ab,kw.
 33 28 22 or 23 or 24 or 25 or 26 or 27
 34 29 exp Diabetes Mellitus/
 35 30 diabetes.ti,ab,kw.
 36 31 29 or 30
 37 32 exp Hepatitis/
 38 33 exp Colitis/
 39 34 (hepatitis or hepatocellular injur* or colitis).ti,ab,kw.
 40 35 32 or 33 or 34
 41 36 "Autoimmune Diseases of the Nervous System"/
 42 autoimmune disease*.ti,ab,kw.
 43 38 Musculoskeletal Diseases/
 44 musculoskeletal.ti,ab,kw.
 45 39 36 or 37 or 38 or 39
 46 40 6 or 10 or 16 or 21 or 28 or 31 or 35 or 40
 47 42 exp Hospitalization/ or exp Intensive Care Units/ or Inpatients/ or Subacute Care/
 48 (hospital or hospitalized or hospitalization or intensive or ICU or care or post?acute or
 49 inpatient or inpatients or admit or admitted or admitting).ti,ab,kw.
 50 44 42 or 43
 51 45 3 and 41 and 44
 52 46 limit 45 to english language
 53 47 limit 46 to yr="2019 -Current"

136/bmjopen-2022-061221 on August 2022. Downloaded from <http://bmjopen.bmj.com/> on April 19, 2024 by guest. Protected by copyright.

Supplemental Table 2. Study Characteristics for Studies with Control Groups

Author, Year Country Study Design Funding	Inclusion/Exclusion Criteria	Baseline Demographic Data	Hospitalization Characteristics Time of Post-hospital Follow-up
Al-Aly, 2021(1) USA (Veterans) Retrospective Funding: VA	<p>Inclusion: Admitted for COVID-19 within 30 days after or 5 days before first positive test and survived at least 30 days after hospital admission; selected from 98,661 patients with positive COVID-19 test between March 01, 2020 and November 30, 2020</p> <p>Exclusion: None specified</p> <p>Controls: hospitalized for seasonal influenza between October 01, 2016 and February 29, 2020; survived 30 days after hospital admission</p> <p>Propensity scores based on predefined variables were estimated to adjust for potential confounders</p>	<p>N=13,654 (COVID-19 group); N=13,997 (Control group) Age (years, mean): 70 (COVID-19 and Control groups) Gender (% male): 94 (COVID-19 and Control groups) Race/ethnicity: COVID-19 group: White 59%, Black 34%; Control group: White 73%, Black 22%</p> <p>Comorbidities: NR</p>	<p>COVID-19 severity: NR</p> <p>ICU admission: 26% (n=3586)</p> <p>Respiratory support Mechanical ventilation or ECMO: NR NIV, HFNC, or CPAP: NR Other: NR</p> <p>Length of hospital stay: NR</p> <p>Planned time post-hospital in patients that survived 30 days after diagnosis (days): 180</p> <p>Reported time post-hospital (days, median): COVID-19 group: 150, Control group: 157</p>
Ayoubkhani, 2021(2) United Kingdom Retrospective Funding: none	<p>Inclusion: Hospitalized for COVID-19, (positive laboratory test or clinical diagnoses) from January 1, 2020 to end of August 2020</p> <p>Exclusion: Not discharged alive by August 31, 2020 or birth date or gender unknown</p> <p>Controls: individuals in general population, did not meet inclusion criteria for COVID-19, and had not died before January 1, 2020; 79% had prior hospital admission</p>	<p>N=47,780 (for both COVID-19 group and matched control group) Age (%): COVID-19 group Age <30: 5; 30-49: 16; 50-69: 33; ≥70: 46 Control group <30: 3; 30-49: 19; 50-69: 33; ≥70: 46 Gender (% male): 55 (COVID-19 and Control groups) Race/ethnicity: White 72%, Asian 9%, Black 5% (COVID-19 and Control groups)</p> <p>Comorbidities:</p>	<p>COVID-19 severity: NR</p> <p>ICU admission: 10% (n=4745)</p> <p>Respiratory support: NR</p> <p>Length of hospital stay: NR</p> <p>Planned time post-hospital: NR</p> <p>Reported time post-hospital (days, mean): COVID-19 group: 140, Control group: 153</p>

136/bmjopen-2022-012498 on 24 August 2022. Downloaded from <http://bmjopen.bmj.com/> by guest. Protected by copyright.

Author, Year Country Study Design Funding	Inclusion/Exclusion Criteria	Baseline Demographic Data	Hospitalization Characteristics Time of Post-hospital Follow-up
Chevinsky 2021(3) USA Retrospective Funding: Not reported	Patients and controls matched (1:1) on several confounding variables; all were active patients in National Health Service	MACE: 24% (COVID-19 and Control groups) CKD: 13% (COVID-19 and Control groups) COPD: COVID-19 group: 14%; Control group: 12% DM: 24% (COVID-19 and Control groups) HTN: 52% (COVID-19 and Control groups) Obesity (BMI ≥30): 32% (COVID-19 and Control groups) Smoking: 8% current, 41% former (COVID-19 and Control groups)	COVID-19 severity: NR ICU admission: both groups 40% Respiratory support: NR Length of hospital stay (days, median): COVID-19 group 6 (range 3, 11); Control group 4 (range 2, 6) Planned time post-hospital (days): 30-120 Reported time post-hospital (days): NR
Daugherty 2021(4) USA	Inclusion: Ages 18-65 diagnosed with COVID-19 (SARS-CoV-2); continuous enrollment in the health plan from January	N=27,284 adults for both COVID-19 and Control groups Age (%): COVID-19 group Age 18-39: 9; 40-49: 10; 50-64: 28; ≥65: 53 Control group Age 18-39: 11; 40-49: 9; 50-64: 27; ≥65: 54 Gender (% male): COVID-19 group: 48; Control group: 47 Race/ethnicity: COVID-19 group: White 48%, Black 26%, Asian 2%, Hispanic 13% Control group: White 47%, Black 26%, Asian 2%, Hispanic 14%	Comorbidities: NR COVID-19 severity: NR ICU admission: 13% (n=2933)

136/bmjopen-2022-012159 on 24 August 2023, downloaded from <http://bmjopen.bmj.com/> on April 18, 2024 by guest. Protected by copyright.

Author, Year Country Study Design Funding	Inclusion/Exclusion Criteria	Baseline Demographic Data	Hospitalization Characteristics Time of Post-hospital Follow-up
Retrospective Funding: Insurance (Research & Development)	<p>1, 2019 to index date (defined by first of: 1) primary, secondary, or tertiary diagnosis of COVID-19; 2) administrative claims with ICD-10 codes U07.1 or either B34.2 or B97.29 before April 1, 2020; 3) documentation of positive PCR test in outpatient laboratory dataset; or 4) admitted to hospital for COVID-19 (based on diagnostic code))</p> <p>Exclusion: Positive SARS-CoV-2 antibodies but without documented infection; ICD-10 codes B34.2 or B97.29 on or after April 1, 2020; and admitted to hospital for suspected COVID-19 but missing diagnostic codes</p> <p>Controls: ages 18-65 without COVID-19 (SARS-CoV-2) diagnosis with continuous health plan enrollment from January 1 2019 to randomly assigned month and day drawn from the SARS-CoV-2 infection group (2020 comparator group used for analysis of hospitalized patients)</p> <p>Patients and controls matched (1:1) using propensity scores based on 108 variables</p>	<p>exclusion if less than index date + 21 days of follow-up); demographics and comorbidities NR for hospitalized subgroup Age (years, mean): NR Gender (% male): NR Race/ethnicity: NR</p> <p>Comorbidities: NR</p>	<p>Respiratory support: NR Length of hospital stay: NR Planned time to <u>post-acute infection*</u> (days): 90-180 Reported time to <u>post-acute infection*</u> (days, mean): 120</p> <p>NOTE: post-acute infection defined as index date plus 21 days</p>
Nugent, 2021(5) USA Retrospective Funding: Foundation	<p>Inclusion: Tested for COVID-19 by RT-PCR, developed AKI during hospitalization, survived past discharge, did not require dialysis within 3 days of discharge, had ≥1 measurement of serum creatinine as an outpatient post-discharge</p>	<p>N=1612 (182 COVID-19) Age (years, median): 70 (67 COVID-19 group) Gender (% male): 50 (53 COVID-19 group) Race/ethnicity: 40% Black, 41% White, 3% Asian, 17% Other; 22% Hispanic (COVID-19 group)</p>	<p>COVID-19 severity: NR ICU admission: 37% (COVID-19 group) Respiratory support Mechanical ventilation or ECMO: 29% (COVID-19 group)</p>

Author, Year Country Study Design Funding	Inclusion/Exclusion Criteria	Baseline Demographic Data	Hospitalization Characteristics Time of Post-hospital Follow-up
Puntmann, 2020(6) Germany Prospective Funding: Government, Industry, Institution	<p>Exclusion: Age <18 years, determined to have ESKD, received prior kidney transplant, initial creatinine level \geq4 mg/dL</p> <p>Controls: hospitalized patients with AKI and negative test for COVID-19</p> <p>Inclusion: Minimum of 2 weeks post-diagnosis of SARS-CoV-2 by RT-PCR; resolution of respiratory symptoms; negative results on swab test at end of isolation period</p> <p>Exclusion: Recently recovered from COVID-19 and referred for clinical CMR imaging; unwilling to participate; absolute contraindications for contrast-enhanced magnetic resonance study</p> <p>Controls: healthy and risk-factor matched groups</p>	<p>Comorbidities: CVD: NR CKD: 35% (33% COVID-19 group) COPD: 47% (45% COVID-19 group) DM: 52% (64% COVID-19 group) HTN: 89% Obesity: NR Smoking: NR</p> <p>N=100 Age (years, mean): 49 Gender (% male): 53 Race: NR</p> <p>Comorbidities: CVD: 13% CKD: NR COPD: 21% DM: 18% HTN: 22% Obesity: NR Smoking: 22%</p>	<p>NIV, HFNC, or CPAP: NR Other: NR</p> <p>Length of hospital stay (days, mean): 14 (COVID-19 group)</p> <p>Planned time post-hospital: NR</p> <p>Reported time post-hospital (days, median): 93 (COVID-19 group)</p> <p>COVID-19 severity: 18% asymptomatic, 49% mild/moderate (both recovered at home), 33% severe (required hospitalization)</p> <p>ICU admission: NR</p> <p>Respiratory support Mechanical ventilation or ECMO: 2%, 6% (hospitalized group) NIV, HFNC, or CPAP: 17%, 52% (hospitalized group) Other: 28% (NR for hospitalized group)</p> <p>Length of hospital stay: NR</p> <p>Planned/reported time post-hospital: NR</p> <p>NOTE: median time from diagnosis to CMR was 71 [IQR 64-92] days)</p>

136/bmjopen-2022-012491, doi:10.1136/bmjopen-2022-012491, downloaded from http://bmjopen.bmj.com/ on 15 August 2024 by guest. Protected by copyright.

136/bmjopen-2022-012150 on August 18, 2024. Protected by copyright.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Author, Year Country Study Design Funding	Inclusion/Exclusion Criteria	Baseline Demographic Data	Hospitalization Characteristics Time of Post-hospital Follow-up
Raman, 2021(7) United Kingdom Prospective Funding: Government, Foundation	Inclusion: All patients with moderate to severe laboratory COVID-19 (positive SARS-CoV-2) Exclusion: Severe comorbidities (end-stage renal, cardiac, liver, or neurological disease), contradictions to MRI Controls: uninfected (negative for SARS-CoV-2 and asymptomatic), from the community (not hospitalized), group-matched for age, sex, body mass index, and risk factors	N=58 COVID-19 Age (years, mean): 55 Gender (% male): 59 Race/ethnicity: 22% Black/Asian and minority ethnic groups; 78% White Comorbidities: CAD: 3% CKD: NR COPD: 5% DM: 16% (Type 1 and 2) HTN: 38% Obesity: NR Smoking: 35% Current or ex-smoker	COVID-19 severity: Moderate to severe (inclusion criteria) ICU admission: 36% (21/58) Respiratory support Mechanical ventilation or ECMO: 21% NIV, HFNC, PAP: 26% Other: 46% Length of hospital stay (days, median): 8.5 Planned time post-hospital (days): 30-180 Reported time post-hospital (days, median): 48
Roberts, 2020(8) United Kingdom Prospective Funding: Not reported	Inclusion: Patients discharged following admission for COVID-19; 6-week follow-up for hospital-associated VTE (HA-VTE) events Exclusion: None reported NOTES: 1) patients received thromboprophylaxis while hospitalized Controls: cohort of post-discharge HA-VTE following medical admission in 2019	N=1877 Age (years, mean): NR Gender (% male): NR Race: NR Comorbidities: NR	COVID-19 severity: NR ICU admission: NR (11% [208/1877] admitted to critical care) Respiratory support: NR Length of hospital stay: NR Planned/reported time post-hospital (days): 90

Author, Year Country Study Design Funding	Inclusion/Exclusion Criteria	Baseline Demographic Data	Hospitalization Characteristics Time of Post-hospital Follow-up
Xiong, 2021(9) China Prospective Funding: Not reported	Inclusion: Ages 20-80 years, diagnosed with COVID-19, cured and discharged Exclusion: Severe and complex underlying diseases, receiving invasive treatment, women who were pregnant or breastfeeding Controls: free of COVID-19, similar demographics, completely quarantined at home for >3 months with little physical work	N=538 (those who completed telephone follow-up from group of 891 discharged) Age (years, median): 52 Gender (% male): 46 Race/ethnicity: NR Comorbidities: CHD: 3% CKD: 2% COPD: 4% DM: 7% HTN: 15% Obesity: NR Smoking: NR	COVID-19 severity: 5% critical, 34% severe, 62% general” ICU admission: NR Respiratory support: NR Length of hospital stay: NR Planned time post-hospital: NR Reported time post-hospital (days, median): 97

Abbreviations: AKI=acute kidney injury; CAD=coronary artery disease; CKD=chronic kidney disease; CMR=cardiovascular magnetic resonance; COPD=chronic obstructive pulmonary disease; COVID-19=SARS-CoV-2: 2019 novel coronavirus; CPAP=continuous positive airway pressure; CVD=cardiovascular disease; DM=diabetes mellitus; ECMO=extracorporeal membrane oxygenation; ESKD=end stage kidney disease; HFNC=high-flow nasal cannula; HTN=hypertension; ICD=International Classification of Disease; IQR=interquartile range; ICU=intensive care unit; MRI=magnetic resonance imaging; NIV=non-invasive ventilation; NR=not reported; RT-PCR: reverse transcriptase polymerase chain reaction; VTE=venous thromboembolism; WHO=World Health Organization

Supplemental Table 3. Included Studies and Outcomes Reported

Author, year Country Sample Size (COVID-19/ control) Description of Controls	ICU Admission (%) Assessment Time Post- Discharge	Pulmonary Outcomes	Cardio- vascular Outcomes	Neurologic and Cognitive Outcomes	Renal Outcomes	Endocrine Outcomes	Gastro- intestinal Outcomes	Hematologic Outcomes
Al-Aly, 2021(1) USA 13,654/13,997 Historical controls; hospitalized for seasonal Influenza and survived 30 days after admission; propensity scores based on pre-defined variables estimated to adjust for potential confounders	26% COVID-19: 150 days Controls: 157 days (median)	Shortness of breath HR (adjusted) 1.14 (95%CI 1.04, 1.26) Excess burden per 1000 hospitalized COVID-19 patients at 6 months 13.22 (95%CI 3.68, 21.94)	Acute coronary disease^a HR (adjusted) 1.29 (95%CI 1.11, 1.50) Excess burden per 1000 hospitalized COVID-19 patients at 6 months 9.36 (95%CI 4.16, 13.86) Heart Failure^a HR (adjusted) 1.19 (95%CI 1.03, 1.39) Excess burden per 1000 hospitalized COVID-19 patients at 6 months 6.31 (95% CI 1.02, 10.88)	Stroke^a HR (adjusted) 1.30 (95%CI 1.05, 1.60) Excess burden per 1000 COVID-19 persons at 6 months 4.79 (95%CI 1, 7.87) Neuro- cognitive Disorders^a Excess burden per 1000 COVID-19 persons at 6 months 16.16 (95%CI 10.40, 21.19) Memory problems^a HR (adjusted) 1.42 (95%CI 1.23, 1.63) Excess burden per 1000	AKI^a HR (adjusted) 1.24 (95%CI 1.10, 1.40) Excess burden per 1000 COVID-19 persons at 6 months 11.21 (95%CI 5.36, 16.43) CKD^a HR (adjusted) 1.35 (95%CI 1.10, 1.65) Excess burden per 1000 COVID-19 persons at 6 months 6.03 (95%CI 2.17, 9.20)	Diabetes^a HR (adjusted) 1.60 (95%CI 1.36, 1.87) Excess burden per 1000 hospitalized COVID-19 patients at 6 months 21.39 (95%CI 15.10, 26.77)	“Gastro- intestinal Disorders” (includes dysphagia) ^a Excess burden per 1000 COVID-19 persons 19.28 (95%CI 12.75, 25.13)	Thrombo- embolism^a HR (adjusted) 2.26 (95% CI 1.94, 2.64) 25.74, 33.24) Pulmonary Embolism^a Excess burden per 1000 COVID-19 persons at 6 months 18.31 (95%CI 15.83, 20.25) Coagulation Disorder^a Excess burden per 1000 COVID-19 persons at 6 months 14.31 (95%CI 10.08, 17.89)

Author, year Country Sample Size (COVID-19/ control) Description of Controls	ICU Admission (%) Assessment Time Post- Discharge	Pulmonary Outcomes	Cardio- vascular Outcomes	Neurologic and Cognitive Outcomes	Renal Outcomes	Endocrine Outcomes	Gastro- intestinal Outcomes	Hematologic Outcomes
				COVID-19 persons at 6 months 16.59 (95%CI 10.59, 21.84)				
Ayoubkhani, 2021(2) United Kingdom 47,780/47,780 Concurrent controls, general population, not meeting inclusion criteria for COVID-19; ≥1 record in general practice database in past year (ie, active patients); matched (1:1) on demographic and comorbidity factors	10% COVID-19: 140 days Controls 153 days (mean)	Respiratory Disease, new onset events COVID-19: 21.5% Control: 0.8% P<.001	MACE, new onset events COVID-19: 2.6% Control: 0.5% P<.001	NR	CKD, new onset events COVID-19: 0.6% Control: 0.3%	Diabetes, new onset events COVID-19: 1.1% Control: 0.3% P<.001	Chronic Liver Disease, new onset COVID-19: 0.2% Control: 0.04% P<.001	NR
Chevinsky, 2021(3) USA 27,284/27,284	40% COVID-19/ Controls	Respiratory failure; insufficiency; arrest	NR	Neuro- cognitive disorders 90-120 days after discharge	Acute and unspecified kidney failure 90-120 days after discharge	NR	NR	Acute Pulmonary Embolism 90-120 days after discharge

136/bmjopen-2022-061245 on 24 August 2022. Downloaded from <http://bmjopen.bmj.com/> on April 19, 2024 by guest. Protected by copyright.

Author, year Country Sample Size (COVID-19/ control) Description of Controls	ICU Admission (%) Assessment Time Post- Discharge	Pulmonary Outcomes	Cardio- vascular Outcomes	Neurologic and Cognitive Outcomes	Renal Outcomes	Endocrine Outcomes	Gastro- intestinal Outcomes	Hematologic Outcomes
Concurrent controls, hospitalized, did not meet inclusion for COVID-19; no diagnosis of COVID-19 during 4 months after index encounter; matched (1:1) on demographic, comorbidity, and socioeconomic factors	30-120 days (planned)	90-120 days after discharge OR (adjusted) 0.73 (95%CI 0.47, 1.10) Pneumonia (except that caused by tuberculosis) 90-120 days after discharge OR (adjusted) 1.00 (95%CI 0.58, 1.90)		OR (adjusted) 1.10 (95%CI 0.72, 1.70)	OR (adjusted) 0.56 (95%CI 0.39, 0.80)			OR (adjusted) 1.2 (95%CI 0.70, 2.10) Coagulation and Hemorrhagic Disorders 90-120 days after discharge OR (adjusted) 0.66 (95%CI 0.45, 0.97)
Daugherty, 2021(4) USA 18,118/18,118 Concurrent controls; no clinical diagnosis related to COVID-19, no positive test for SARS-CoV-2,	13% COVID-19/ Controls=120 days (mean)	New Clinical Diagnoses: Respiratory failure (acute respiratory failure, chronic respiratory failure, interstitial lung disease) COVID-19: 2.6% Control: 0.2%	New Diagnoses Coronary disease overall (MI, acute coronary syndrome, cardiogenic shock) COVID-19: 1.1% Control: 0.2% P<.001	Stroke (ischemic and hemorrhagic) COVID-19: 1.1% Control: 0.3% P<.001 New Clinical Diagnoses Amnesia/ memory difficulty	Kidney injury (acute and chronic) COVID-19: 3.0% Control: 0.8% Acute kidney injury COVID-19: 2.9% Control: 0.5% CKD	New Clinical Diagnoses Diabetes (Type 2) COVID-19: 3.0% Control: 0.8% P<.001	Liver Test Abnormality COVID-19: 3.3% Control: 1.4% P<.001	DVT COVID-19: 2.3% Control: 0.30% PE COVID-19: 1.3% Control: 0.1% P<.001 for all outcomes Hyper-coagulability COVID-19: 3.2% Control: 0.4%

Author, year Country Sample Size (COVID-19/ control) Description of Controls	ICU Admission (%) Assessment Time Post- Discharge	Pulmonary Outcomes	Cardio- vascular Outcomes	Neurologic and Cognitive Outcomes	Renal Outcomes	Endocrine Outcomes	Gastro- intestinal Outcomes	Hematologic Outcomes
no hospital admission for COVID-19, continuous health plan enrollment in past year, matched (1:1) on demographic, comorbidity, and provider visit factors		Risk difference 2.4% (95%CI 1.35, 3.20) Acute respiratory failure COVID-19: 2.6% Control: 0.18% Risk difference 2.4% (95%CI 1.67, 3.43) Chronic respiratory failure COVID-19: 1.5% Control: 0.1% Risk difference 1.5% (95%CI 0.97, 1.75) Interstitial lung disease COVID-19: 1.6% Control: 0.1%	Congestive Heart Failure COVID-19: 1.5% Control: 0.2% P<.001 Myocarditis COVID-19: 0.09% Control: 0.01% P=1.0	COVID-19: 2.9% Control: 0.4% P<.001 Dementia COVID-19: 0.2% Control: 0.03% P<.001 Alzheimer COVID-19: 0.04% Control: 0.0% P<.001	COVID-19: 2.1% Control: 0.7% P<.001 for both outcomes			P<.001

136/bmjopen-2022-061245 on 24 August 2022. Downloaded from <http://bmjopen.bmj.com/> on April 19, 2024 by guest. Protected by copyright.

Author, year Country Sample Size (COVID-19/ control) Description of Controls	ICU Admission (%) Assessment Time Post- Discharge	Pulmonary Outcomes	Cardio- vascular Outcomes	Neurologic and Cognitive Outcomes	Renal Outcomes	Endocrine Outcomes	Gastro- intestinal Outcomes	Hematologic Outcomes
		Risk difference 1.5% (95%CI 1.14, 1.98) P<.001 for all outcomes						
Nugent, 2021(5) USA 182/1430 Concurrent controls; hospitalized, with AKI, negative test for COVID-19; analysis adjusted for demographic, comorbidity, and kidney function factors	37% COVID- 19=93 days Controls=61 days	NR	NR	NR	Kidney Recovery after Discharge (rate per 100 patient- days) COVID-19 Group (n=32) 0.95 (0.62, 1.46) Non-COVID Group (n=287) 1.74 (1.51, 2.00) HR (adj): 0.57 (0.35, 0.92); P=.02	NR	NR	NR
Puntmann, 2020(6) Germany 100 ^b /50 healthy controls/57 risk- factor matched controls	NR COVID-19/ Controls=NR (median time from diagnosis to	NR	CMR LGE Myocardial COVID-19: 32% Control: 0% Risk Factor- matched Control: 17%	NR	NR	NR	NR	NR

13616/mjopen-2022-061245 on 24 August 2022. Downloaded from <http://bmjopen.bmj.com/> on April 19, 2024 by guest. Protected by copyright.

Author, year Country Sample Size (COVID-19/ control) Description of Controls	ICU Admission (%) Assessment Time Post- Discharge	Pulmonary Outcomes	Cardio- vascular Outcomes	Neurologic and Cognitive Outcomes	Renal Outcomes	Endocrine Outcomes	Gastro- intestinal Outcomes	Hematologic Outcomes
<p>only 33% of COVID-19 group was hospitalized</p> <p>Healthy controls: normotensive, taking no cardiac medications, normal cardiac volume and function</p> <p>Risk-factor matched: pre-COVID patients, matched on demographic and comorbidity factors including known coronary artery disease</p>	<p>CMR was 71 days)</p>		<p>P<.05</p> <p>Pericardial COVID-19: 22% Control: 0% Risk Factor- matched Controls: 14%</p> <p>Pericardial Effusion >10 mm COVID-19: 20% Control: 0% Risk Factor- matched Control: 7% P<.05</p> <p>Detectable hsTNT ≥3 pg/mL COVID-19: 71% Control: 22% Risk Factor- matched Control: 54% P<.05</p> <p>Significantly elevated hsTNT ≥13.9 pg/mL</p>					

Author, year Country Sample Size (COVID-19/ control) Description of Controls	ICU Admission (%) Assessment Time Post- Discharge	Pulmonary Outcomes	Cardio- vascular Outcomes	Neurologic and Cognitive Outcomes	Renal Outcomes	Endocrine Outcomes	Gastro- intestinal Outcomes	Hematologic Outcomes
			COVID-19: 5% Control: 0% Risk Factor- matched Control: 0% P<.05					
Raman, 2021(7) United Kingdom 58/30 Concurrent controls; community dwelling, negative for SARS-CoV-2 and asymptomatic, group matched for demographic and comorbidity factors	36% COVID-19 36 days (median) Controls not applicable	FVC <80% Predicted COVID-19: 13% Control: 0% P=.09 FEV₁<80% Predicted COVID-19: 10.7% Control: 0.4% P=.42 Dyspnea – mMRC ≥2 (significant breathlessness) COVID-19: 64.3% Control: 10.3% P<.0001 Lung Parenchymal Abnormalities COVID-19: 60.4% Control: 10.7%	Left Ventricular Function Normal and comparable between groups (data NR) LGE Myocarditis COVID-19: 12% Controls: 7% P=.47 Pericardial Effusion >10 mm COVID-19: 2% Controls: 0% P=1.0 Abnormal Troponin T COVID-19 0% Controls 0%	MoCA <26 (Abnormal) COVID-19: 28% Control: 17% P=.30 (calculated)	Residual Renal Impairment, new onset COVID-19: 3%	NR	NR	NR

Author, year Country Sample Size (COVID-19/ control) Description of Controls	ICU Admission (%) Assessment Time Post- Discharge	Pulmonary Outcomes	Cardio- vascular Outcomes	Neurologic and Cognitive Outcomes	Renal Outcomes	Endocrine Outcomes	Gastro- intestinal Outcomes	Hematologic Outcomes
		P<.0001 VO₂ Peak <80% of Predicted Maximum COVID-19: 54.9% Control: 7.4% P<.0001						
Roberts, 2020(8) United Kingdom 1,877/18,159 Historical controls; discharged from hospital following medical admission (pre- COVID)	11% critical care COVID-19/ Controls=8 days (median)	NR	NR	NR	NR	NR	NR	VTE COVID-19: 0.5% 2 DVT, 7 PE Control (Medical Admissions in 2019): 0.3% 8 proximal, 10 distal, 5 line- associated upper-limb DVT, 33 PE OR 1.60 (95%CI 0.77, 3.10) P=.2
Xiong, 2021(9) China 538/184 Concurrent controls; non hospitalized,	NR COVID-19/ Controls=97 days (median)	NR	Newly Diagnosed Hypertension COVID-19: 1% Control: 0%	NR	NR	NR	NR	NR

136/bmjopen-2022-061245 on 24 August 2022. Downloaded from <http://bmjopen.bmj.com/> on April 19, 2024 by guest. Protected by copyright.

136/bmjopen-2022-061245 on 24 August 2022
Downloaded from <http://bmjopen.bmj.com/> on April 18, 2024 by guest. Protected by copyright.

Author, year Country Sample Size (COVID-19/ control) Description of Controls	ICU Admission (%) Assessment Time Post- Discharge	Pulmonary Outcomes	Cardio- vascular Outcomes	Neurologic and Cognitive Outcomes	Renal Outcomes	Endocrine Outcomes	Gastro- intestinal Outcomes	Hematologic Outcomes
non-COVID with similar demographics								

^aIncludes participants without history of the outcome in the past one year

Abbreviations: AKI=acute kidney injury; CI=confidence interval; CKD=chronic kidney disease; CMR=cardiovascular magnetic resonance; COVID-19=SARS-CoV-2: 2019 novel coronavirus; DVT=deep venous thrombosis; FEV1 =forced expiratory volume in 1 sec; FVC=forced vital capacity; HR=hazard ratio; hsTNT=high-sensitivity Troponin T; LGE=late gadolinium enhancement; LVEF=left ventricular ejection fraction; mMRC=modified Medical Research Council; MoCA=Montreal Cognitive Assessment; MRI=magnetic resonance imaging; NR=not reported; OR=odds ratio; PE=pulmonary embolism; VTE=venous thromboembolism

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Supplemental Table 4. Quality Ratings for Studies with Control Groups (shaded columns are database studies)

Criteria*	Al-Aly 2021(1)	Ayoubkhani 2021(2)	Chevinsky 2021(3)	Daugherty 2021(4)	Nugent 2021(5)	Puntmann 2020(6)	Raman 2021(7)	Roberts 2020(8)	Xiong 2021(9)
Were groups similar/recruited from same population?	No	No	Yes	No	Yes	Unclear	No	No	No
Was exposure measured similarly?	N/A	N/A	Yes	Yes	Yes	N/A	Yes	N/A	Unclear
Was exposure measured in valid and reliable way?	Yes	Yes	Unclear	Unclear	Yes	Yes	Yes	Unclear	Unclear
Were confounding factors identified?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Unclear	Unclear
Were strategies to deal with confounding factors stated?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	No
Were participants free of outcome at moment of exposure?	Yes	Yes	Yes	Yes	Yes	Unclear	Unclear	Unclear	Yes
Were outcomes measured in a valid and reliable way?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Unclear

view only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

136/bmjopen-2022-025125 on 24 August 2022. Downloaded from <http://bmjopen.bmj.com/> on April 18, 2024 by guest. Protected by copyright.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Criteria*	Al-Aly 2021(1)	Ayoubkhani 2021(2)	Chevinsky 2021(3)	Daugherty 2021(4)	Nugent 2021(5)	Puntmann 2020(6)	Rangan 2021(7)	Roberts 2020(8)	Xiong 2021(9)
Was follow-up time reported and sufficient† for outcomes to occur?	Yes	Yes	Yes	Yes	Yes	Unclear	No	Yes	Yes
Was follow-up complete? If not, were reasons for loss described and explored?	Yes	Yes	Unclear	Yes	No/Yes – described	Yes	Yes	No/No	No/Yes - described
Were strategies to address incomplete follow-up utilized?	N/A	N/A	Unclear	N/A	Yes	N/A	No	No	No
Was appropriate statistical analysis used?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

N/A=not applicable

*JBI Critical Appraisal Checklist for Cohort Studies. Source: Moola S, Munn Z, Tufanaru C, et al. Chapter 7: Systematic reviews of etiology and risk. In Aromataris E, Munn Z (Eds) JBI Manual for Evidence Synthesis. JBI, 2020. Available from <https://synthesismanual.bji.global>. Accessed October 8, 2021.

†For this manuscript, ≥90 days was considered sufficient

Supplemental Table References

1. Al-Aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19. *Nature*. 2021;594(7862):259-64.
2. Ayoubkhani D, Khunti K, Nafilyan V, Maddox T, Humberstone B, Diamond I, et al. Post-covid syndrome in individuals admitted to hospital with covid-19: retrospective cohort study. *BMJ*. 2021;372:n693.
3. Chevinsky JR, Tao G, Lavery AM, Kukielka EA, Click ES, Malec D, et al. Late conditions diagnosed 1-4 months following an initial COVID-19 encounter: a matched cohort study using inpatient and outpatient administrative data - United States, March 1-June 30, 2020. *Clin Infect Dis*. 2021;73:S5-S16.
4. Daugherty SE, Guo Y, Heath K, Dasmariñas MC, Jubilo KG, Samranvedhya J, et al. Risk of clinical sequelae after the acute phase of SARS-CoV-2 infection: retrospective cohort study. *BMJ*. 2021;373(n1098).
5. Nugent J, Akilu A, Yamamoto Y, Simonov M, Li F, Biswas A, et al. Assessment of acute kidney injury and longitudinal kidney function after hospital discharge among patients with and without COVID-19. *JAMA Netw Open*. 2021;4(3):e211095.
6. Puntmann VO, Carerj ML, Wieters I, Fahim M, Arendt C, Hoffman J, et al. Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19). *JAMA Cardiol*. 2020;5(11):1265-73.
7. Raman B, Cassar MP, Tunnicliffe EM, Filippini N, Griffanti L, Alfaro-Almagro F, et al. Medium-term effects of SARS-CoV-2 infection on multiple vital organs, exercise capacity, cognition, quality of life and mental health, posthospital discharge. *EClinicalMedicine*. 2021;31:100683.
8. Roberts LN, Whyte MB, Georgiou L, Giron G, Czuprynska J, Rea C, et al. Postdischarge venous thromboembolism following hospital admission with COVID-19. *Blood*. 2020;136(11):1347-50.
9. Xiong Q, Xu M, Li J, Liu Y, Zhang J, Xu Y, et al. Clinical sequelae of COVID-19 survivors in Wuhan, China: a single-centre longitudinal study. *Clin Microbiol Infect*. 2021;27(1):89-95.

136/bmjopen-2022-061245 on 24 August 2022. Downloaded from <http://bmjopen.bmj.com/> on April 18, 2024 by guest. Protected by copyright.

PRISMA Checklist

Section/topic	#	Checklist item	Reported on page #
TITLE			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	2-3
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known.	4
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	4
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	3
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	5/Table 1
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	5
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	5/Suppl Table 1
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	5
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	6

Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	6
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	7
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	N/A
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I^2) for each meta-analysis.	7
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	N/A
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	N/A
RESULTS			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	7/Figure
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	7-8/Suppl Table 2
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	8-9/Suppl Table 4
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	9-16/Suppl Table 3
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	N/A
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	N/A
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	N/A
DISCUSSION			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	16-17

136/bmjopen-2022-061245 on 24 August 2022. Downloaded from <http://bmjopen.bmj.com/> on April 18, 2024 by guest. Protected by copyright.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review level (e.g., incomplete retrieval of identified research, reporting bias).	16-17
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	17-18
FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	7, 19

Source: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097